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ABSTRACT  
Nanotheranostics is one of the biggest scientific breakthroughs in nanomedicine. Most of the 
currently available diagnosis and therapies are invasive, time-consuming and associated with 
severe toxic side effects. Nanotheranostics, on the other hand, has the potential to bridge this 
gap by harnessing the capabilities of nanotechnology and nanomaterials for combined 
therapeutics and diagnostics with markedly enhanced efficacy. However, nanomaterial 
applications in nanotheranostics are still in its infancy. This is due to the fact that each 
disease has a particular microenvironment with well-defined characteristics, which promotes 
deeper selection criteria of nanomaterials to meet the disease needs. In this review, we have 
outlined how nanomaterials are designed and tailored for nanotheranostics of cancer, and 
other diseases such as neurodegenerative, autoimmune (particularly on rheumatoid arthritis) 
and cardiovascular diseases. The penetrability and retention of a nanomaterial in the 
biological system, the therapeutic strategy used and the imaging mode selected are some of 
the aspects discussed for each disease. The specific properties of the nanomaterials in terms 
of feasibility, physicochemical challenges, progress in clinical trials, its toxicity and their 
future application on translational medicine are addressed. Our review meticulously and 
critically examines the applications of nanotheranostics with various nanomaterials, including 
graphene, across several diseases; offering a broader perspective of this emerging field. 
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John Funkhouser, the PharmaNetics president and CEO, was credited by scientists in year 
2002 for introducing the term theranostics (a portmanteau of Therapeutics and Diagnostics), 
which epitomes the development of nanoparticle system for personalized medicine.1,2 
Theranostics (or theragnostics) refers to comprehensive effort that integrates diagnostic and 
therapy in a single system/platform.3,4  
With the emergence of nanotechnologies and nanomaterials, the concept of nanotheranostics 
was then introduced (Figure 1). Nanotheranostics was able to provide non-invasive imaging, 
targeting and therapy at the disease sites, without affecting surrounding healthy cells.3,5 
Hence, the use of empirical treatment can be avoided (therapy given based on experience, 
usually without a prior definitive medical diagnosis and likely to cause infectious disease), 
greatly improve the prognoses and subsequently expedite clinician’s therapeutic decisions. 
Therefore, early diagnosis will increase the patient’s survival rate, and the optimized 
treatment will contribute to high therapeutic efficiency along with best safety profile.3,6 
Furthermore, over-dosing of drugs and cost of treatment can be effectively reduced. 
Nanotheranostics will also enable real-time monitoring of the drug release and its 
biodistribution in patients.7  
Nanomaterials can be broadly categorized according to their composition, such as metal, 
carbon, inorganic and organic nanoparticles (NPs).8,9 Generally, theranostic nanomaterials 
can be made up of different chemical constructs: targeting moiety (for specific cellular 
binding), therapeutic agents (for drug delivery), diagnostic agents (for non-invasive imaging), 
and polymer coating or matrix that imparts colloidal stability and provide functional groups 
for bio-conjugation.3,6 Some of the important advantages of nanomaterials are undoubtedly 
their small size and large functional surface area to volume ratio, in addition to interesting 
optical and electrical properties. These properties allow the diagnostic and therapeutic agent 
to be adsorbed, dissolved or covalently attached to the surface, to form nanoparticle-
drug/imaging/targeting complexes.10 The complex can subsequently signal (diagnostics) and 
deliver the agents to the cancer cells or other targeted sites to perform the therapy.11,12 
Ideally, after the controlled release of encapsulated drug molecules, the residual nanoparticle 
will be safely degraded and excreted from the body.10  
Recently, the application of nanomaterials with multiple physical imaging modalities and 
therapeutic capabilities has received increasing attention. There are several excellent review 
papers with similar topics made, 8,13–17 however, these papers are either focused on specific 
disease/cancer/illness, or emphasized on the theranostic properties of a specific nanomaterial. 
In this review, we stratify the information on the basis of cancer- or disease-specific, enabling 
comprehensive comparison of the nanomaterials for theranostics of up to three different 
diseases. Specifically, we focus on the nanotheranostics of cancer (including solid and liquid 
tumor) and several diseases: neurodegenerative, autoimmune and cardiovascular diseases (see 
Table 1). The physiochemical properties of various nanomaterials, including graphene, a 
rising star in the 21st century, have been critically reviewed. We also discuss the physical and 
biological barriers that impede application of nanotheranostics in vivo, and provide an 
overview of different nanomaterials that are currently in clinical trials. A future outlook of 
this rapidly growing field will be given as a conclusion. By putting this information together, 
this review may shed light on understanding nanomaterials for nanotheranostics while we are 
expecting continuous breakthrough in this field.
 
Figure 1 Nanotheranostics: The use of nanomaterials with integrated diagnostic and 
therapeutic properties across several diseases.  
Physical and biological barriers that impede the application of nanotheranostics in vivo 
The human body has multi-tiered physical, physiological, chemical and biological barriers to 
protect it against foreign species/substances. Examples of the barriers that nanomaterials may 
encounter in biological systems are the skin, air-blood barrier in the lungs, reproductive 
system, circulation and blood-brain barrier.18,19 Nanomaterials must be precisely engineered 
to overcome these biological barriers and perform nanotherapeutics at the disease site.20 
While it is important to find a balance between therapeutic potential and toxicity of 
nanomaterials, their biological effects on human body are not fully understood due to the 
complexity of nanomaterial/biological barrier interaction. 
In this section, we will discuss the interactions of nanomaterials with serum proteins and 
mononuclear phagocyte system (MPS) in the tumor microenvironment, and provide an 
overview of the barriers to the intratumoral delivery of therapeutic nanomaterials. 
(i) Interaction of nanomaterials with serum proteins  
When nanomaterials circulate throughout the body they are exposed to a complex fluid 
containing blood, lymph, biomolecules, cytoplasm, etc.21,22 Protein and other biomolecules 
such as albumin, transferrin, gamma globulin and fibrinogen, will compete for binding on the 
surface of nanomaterials. This will slightly change the secondary structure of the proteins and 
lead to the formation of both soft and hard protein corona.22–24 Formation of protein corona 
on nanomaterials will affect the surface of nanomaterials and their subsequent interaction 
with biological molecules (biodistribution and penetrance) and cellular compartments.18,25  
The composition, properties and formation of protein corona are influenced by 
physiochemical properties (size, shape, surface area, charge, chemical composition, 
functionalization, colloidal stability, porosity, etc.) of nanomaterials. Nanomaterials could 
exert both positive (act as carriers to immobilize enzyme, improve activity and stability of 
proteins) and negative impacts (induce potential toxicity to cells and organs) on proteins.26 
Supramolecularly built protein corona can also be exploited to shield nanomaterials’ 
interaction with serum proteins and macrophages while retaining its targeting specificity in 
vitro and in vivo.24  
Positively charged nanomaterials facilitate cellular uptake and improve lysosomal escape 
without induction of toxicity, showing more specific interaction with negatively charged 
biological membranes.18 Single-layer and multi-layered graphene oxide have been proven to 
exhibit different behaviors in cell culture medium.27 The various types of carbon 
nanomaterials (fullerene, carbon nanotubes, graphene and their derivatives) have particular 
effects on the structure or activity of the proteins. For instance, the graphene sheet has a 
stronger adsorption capacity for serum proteins than carbon nanotubes. Yet, the enzymatic 
degradation of graphene and fullerenes derivatives is much complicated than carbon 
nanotubes.26  
The individual and in combination properties of nanomaterials play an important role in 
determining their path, biological effect and immunological fate in biological systems.  
(ii) Interaction of nanomaterials with MPS  
One of the factors for low drug-delivery efficacy to the tumor and low therapeutic outcomes 
is due to the MPS. The MPS mainly involves liver, spleen and lymph nodes. MPS serves as a 
delivery barrier for invading pathogens, particulates and dead or damaged host cells.28 
Among the MPS, Kupffer cells are the major phagocytic cells (e.g. macrophages) residing 
inside the liver sinusoid.23 In principle, cationic nanomaterials have higher affinity for 
macrophages than neutral and anionic nanomaterials.23 Attachment of surface protein, such as 
opsonins on the nanomaterials may increase the chance of nanomaterials being recognized by 
the scavenger receptors on the Kupffer cells. This will result in opsonisation and subsequent 
phagocytosis.18,19,23 The nanomaterials will be ultimately taken up and cleared by 
macrophages. Generally, MPS cuts off more than 95 % of the administered nanomaterials.23  
Mammalian cells engulf intracellular contents using autophagosome, a double-membrane 
vesicle, fuse with lysosomes, and later degrade or recycle the autophagic contents. This 
process is known as autophagy.25 Autophagy is vital in maintaining the homeostasis of cells. 
Dysregulation of autophagy in degrading overexpressed prions proteins may lead to 
neurodegenerative disorders; while active autophagy aids in chemotherapeutic treatments of 
cancer cells.25 Fe3O4 NPs were found to have the ability to induce autophagy in human 
cervical carcinoma cells. Positive correlations between size/molecular weight of protein and 
adsorption of protein on a 20 nm Fe3O4 NPs were confirmed.
25 However, the higher the 
adsorption of protein on Fe3O4 NPs, the lower the cell uptake of NPs and consequently lower 
cell autophagy responses.25  
An increase in the dosage of nanomaterials, on the other hand, raises toxicity concerns 
induced by the accumulation of nanomaterials in organs such as liver and spleen.23 Solvents 
and chemicals involved during the synthesis of nanomaterials are one of the causes of toxicity 
in vivo.17 Their long-term cytotoxicity and related immune response should be taken into 
consideration. 
Four strategies (surface modification, tuning of physiochemical properties of nanomaterials, 
biomimetic design inspired by nature and modulation of the MPS) have been identified to 
oppose uptake by the MPS, lower off-target rate and enhance cancer therapeutic efficacy.23 
For instance, modifying the surface of nanomaterials with zwitterions, polyethylene glycol, 
carbohydrate moieties and dysopsonic proteins allow bypass of phagocyte-mediated cellular 
barriers, which in turn increases nanomaterials blood circulation time and theranostics 
efficacy.24 Another interesting strategy to protect the nanomaterials from phagocytosis is by 
using the extracts of cell membranes from blood or tumor cells. The extracts can be used to 
coat the nanomaterials, camouflaging the nanomaterials from uptake by the MPS. 
(iii) Barriers of intratumoral delivery 
Tumor microenvironment is generally composed of tumor cells, the extracellular matrix, 
stromal cells, cells from the immune systems (macrophages, lymphocytes, natural killer 
cells), etc.12,19 Macrophages act as immune cells to maintain immunohomeostasis. The failure 
of existing therapies is mainly attributed to the tumor microenvironment limiting drug access 
to the tumor cells.12,29 This is because upon entering through the blood vessel leakage, 
nanomaterials would interact with the microenvironment factors.  
The intratumoral microenvironment serves as a physical and biological barrier for the 
delivery of therapeutic nanomaterial to the solid tumor (e.g. pancreatic cancer).18 In normal 
tissues, the extracellular matrix is loose and elastic, with sufficient oxygen supply, and the 
overall redox environment is homeostasis.30 In contrast, the basement membrane in the tumor 
is thicker, with higher cross-linked extracellular matrix, hypoxic, acidic and has harsh redox 
environment.31,32 Differentiated macrophages, named as M2-type tumor-associated 
macrophages, will trap and degrade the functional nanomaterials delivered into the tumor.30 
High tumor interstitial fluid pressure will also force the nanomaterials back to blood 
circulation, further preventing them from reaching the tumor sites.30 These 
pathophysiological properties greatly impede intratumoral delivery of nanomaterials.  
Dissolution (or generation of metal ions in target organs and cellular barriers), is another 
common phenomenon in metal and metal oxide nanomaterials in biological systems due to 
their high surface area and reactivity.18 Different strategies, such as the use of stromal 
depletion molecules, targeting of transforming growth factor-beta (TGF-β) and interleukin-6 
(IL-6) pathways, etc. have been studied to overcome the stromal barrier.18,33,34 Pei et al. 
(2019)29 also demonstrated that simultaneous targeting of both TGF-β signaling and KRAS 
mutation attenuates the dense stroma barrier, enhances tumor blood perfusion and improves 
therapeutic efficiency in pancreatic cancer.  
In short, it is important to understand the interaction between nanomaterials and tumor 
microenvironmental factors before constructing functional nanomaterials that are expected to 
be able to overcome the above-mentioned challenges.  
CANCER  
Cancer is a broad name given to the diseases featured with uncontrolled rapid cell division 
that may form growths called tumors. Nobel Laureate Otto Warburg discovered that low 
oxygen was a hallmark of cancer cells. Cancer cells “reprogram” themselves under stressful 
conditions (lack of oxygen, limited nutrient resources or energy, etc.), with a faster growth 
rate than the rate of new blood vessel formation.35,36 
Cancer can be further classified into solid and liquid tumors, each with differences in terms of 
their tumor vascularity and heterogeneity, thus requiring different diagnostic and targeting 
strategies.37 For centuries, surgery, chemotherapy and radiation therapy remain as the most 
common cancer therapies. However, these few alternatives often come with the possibility of 
recurrence after the treatment (since not all cancer cells can be completely removed by 
surgery), severe toxic side effects (chemotherapy and radiotherapy) and limited specificities 
to cancer cells.38,39 Due to their low molecular weight, conventional chemotherapeutic drugs 
generally have low half-lives in the blood and are rapidly distributed in healthy tissues and 
organs, limiting their therapeutic efficacy.40 Furthermore, the use of centralized diagnostic 
platform in most of the cancer management can be complex, time-consuming and not tailored 
to patients and malignancies.37  
Theranostic nanomedicine possess the ability for specific cancer biomarker detection and 
concurrent cancer cells ablation, in a simple and non-invasive way, making them suitable 
candidates for nanotheranostics.37 For instance, the nanomedicine can be delivered and 
accumulated at the tumor sites to perform therapeutic action. Yet, the drug delivery is still 
limited in poorly vascularized regions, some cancer cells are able to continue 
proliferating.10,39 In contrast, liquid tumors (such as leukemia and lymphoma) are spread 
throughout the bloodstream, its diagnostics and therapies are often challenged by poor 
selectivity, low therapeutic efficacy, multi-drug resistance and long-term side effects.37 
Tumor microenvironment varies between cancer types of different or the same anatomical 
region.12 The discovery of the right diagnostics and therapeutics intervention is highly 
important in cancer treatments. 
Continuous research efforts in nanotheranostics from drug delivery vesicles to imaging of 
contrast agents and targeting modalities have rapidly driven nano-oncology towards an all-in-
one, localized early detection and treatment. This section will comprehensively review the 
recent advances regarding the development of different therapies (besides chemotherapy) and 
imaging modalities (such as optical, photoacoustic imaging, magnetic resonance imaging 
(MRI)) for solid and liquid tumors diagnosis and treatment, using functional nanomaterials.  
Solid tumor 
Solid tumor is an abnormal mass of tissues, may be benign (non-cancerous) or malignant 
(cancerous). Examples of solid tumors are carcinomas (tumors formed in epithelial cells) and 
sarcomas (tumors in blood vessels, bones, fat tissues, muscles, etc.).  
Hypoxia, a condition in which the body tissues are deprived of oxygen, mainly due to the 
disorganized vasculature and poor blood circulation, is an important characteristic of solid 
tumors.41,42 The hypoxia microenvironment may confer the resistance of tumors to cancer 
treatment,31 especially photodynamic therapy (PDT), an externally activable and oxygen-
dependent therapeutic modality.38 PDT works by using cytotoxic oxygen species (such as 
singlet oxygen or reactive oxygen species (ROS)) generated from photosensitizer molecules 
upon light exposure, which destruct tissue structure and subsequently kill cancer cells.41 
Besides, solid tumors are 2-3 times more radio-resistant than normoxic tumors.43 Hence, the 
hypoxic and radio-resistance nature of solid tumors cause the cancer treatment even more 
challenging.44  
Intracellular environment of tumor cells is also rich in hydrogen ions (H+) and hydrogen 
peroxide (H2O2) due to rapid glycolytic metabolism and superoxide dismutase over-
expression.45 This contributes to the weakly acidic extracellular pH (pH 6.0-6.8) in tumors, in 
contrast to weakly basic normal tissues (pH 7.2-7.4).5,41 Hence, an ideal solid tumor 
theranostic nanomaterial should be sensitive enough to respond to the minute difference in 
extracellular pH between blood and tumors.46 Other common cancer phenotypes are high 
abundance of antioxidants and elevated glutathione (GSH) level (about 4-fold higher than 
normal cells).5,39,42  
In addition, the original size of the nanocarrier should be maintained below 160 nm for 
optimum deposition on the tumor tissues and exploit the enhanced permeability and retention 
(EPR) effect.47 EPR is a phenomenon where nanomedicine leaks preferentially into tumor 
tissue, through the permeable tumor vasculature. The nanomedicine will be retained in the 
tumor bed owing to the reduced lymphatic drainage.36,48 EPR effect aids in the delivery (with 
a relatively modest effect of less than a 2-fold increase) and accumulation of nanomedicine at 
the solid tumors, and subsequently improves the therapeutic efficacy.23,32,49 The potential side 
effects are greatly reduced, since there is very low accumulation of nanomedicine within the 
normal tissue.36 The ability of the NPs to cluster into large size aggregates after successful 
cellular internalization could prevent the lysosomal exocytosis, which may minimize the loss 
of their therapeutic activity.47 Nevertheless, the drug delivery remains limited in poorly 
vascularized regions of the tumors, some cancer cells are still able to survive.10,18,32 Also, the 
efficiency of EPR effect is highly dependent on cancer type.18 
Researchers have been putting efforts to design and tailor different stimuli-responsive 
nanomaterials to overcome multiple biological and physiological barriers in drug delivery, 
and simultaneously serve as a nanotheranostic platform for cancer. The following section 
provides comprehensive review on the nanotheranostic features of each nanomaterial, 
together with their advantages and limitations.  
Gold nanostructures  
Gold (Au) nanostructure is a collective term given to different shape of gold nanoparticles 
(AuNPs). It has received increasing attention for being able to provide a versatile and 
multifaceted platform for biomedical applications.38,49–51 Apart from having excellent 
biocompatibility and facile surface chemical features, Au nanostructures are able to act as 
photothermal transducers. They are capable of absorbing visible or NIR radiation and then 
convert them into heat with high efficiency to destroy nearby biological structures (coined as 
photothermal therapy, PTT).31,41,42,45,47 The potential side effects of using Au nanostructures 
for cancer treatment can be reduced to minimum by controlling the intensity of light and 
amount of injected nanomaterials, making it a highly selective material in cancer 
treatment.17,52–55  
Hepatocellular carcinoma (HCC), a type of solid tumor, is the most common primary liver 
cancer.56 Being the third leading cause of cancer death worldwide, HCC has often been 
chosen as the focus of many clinical research.57,58 HCC tumors, like other solid tumors, have 
scant stroma and necrosis in the central area due to poor vascularization. HCC is nodular and 
can either appear as a single solitary tumor with a large mass or multiple small tumors.56 A 
tumor microenvironment responsive and triple-synergistic therapeutic nanoplatform based on 
AuNPs with Cu (II)-aptamer complexes has been developed for HCC treatment [Figure 2a 
(ii)].41 Aptamer is a small and easy to synthesize secondary structure ligand made up of single 
DNA or RNA sequence. Aptamers confer lower immunogenicity and have high targeting 
affinity to cell surface receptors,59 whereas chlorin e6 (Ce6) is a widely used 
photosensitiser.38,60 Possessing high singlet oxygen generation capability, Ce6 labelled 
aptamer has been chosen to specifically target the HCC cells and activate PDT. The binding 
of Ce6 labelled aptamer onto AuNPs not only avoids rapid clearance of AuNPs from the 
body, but also serves as a cargo for the Cu (II) coordinated chemotherapeutic prodrug AQ4N 
(or banoxantrone, a hypoxia activated prodrug to enhance anti-tumor effects). The high level 
of intracellular GSH and acidic extracellular pH in cancerous cells induce the release of the 
AQ4N. The electrostatic aggregation of AuNPs induced by the free Cu (II) also switches on 
the PTT effects to ablate solid tumors. This system successfully permits the synergistic 
PDT/PTT/chemotherapy of HCC by single laser irradiation at 670 nm.41 However, this 
approach has some limitations especially when selecting AQ4N as the prodrug. Since AQ4N 
has ultra-high aqueous solubility (260 mg/mL), large dose and multiple dosing (≥ 100 mg/kg) 
are required during combination therapy.61 Although the potential side effects of AQ4N 
loaded nanomedicines have not been reported thus far, low AQ4N loading content and 
encapsulation efficiency, non-specific release and short-term in vivo retention time (half-life 
in vivo ≤ 6 h) are some of the concerns.  
On the other hand, it is technically difficult to keep photoirradiation localized only on cancer 
cells due to uncontrollable distribution of the photothermal agents in the intracellular micro-
environment.62 Alternatively, laser beam allows precise focusing to a tiny region of tumor 
cells. It has therefore been used as a stimulus to cross-link photothermal AuNPs covalently 
with the surface diazirine groups of polyethylene glycol (PEG) ligands [see Figure 2a (i)].63 
Upon 405 nm laser irradiation, diazirine groups generate a highly active carbene intermediate 
that can form covalent bonds with ligands within close proximity of AuNPs. The interparticle 
cross-linking of AuNPs has significantly improved photothermal ablation effects, with an 
optical-thermal conversion efficiency of about 78.8 % as compared to 21.6 % for the non-
cross-linked AuNPs. This innovative approach has effectively shifted the surface plasmon 
resonance of 20.5 nm AuNPs to NIR region. It was also noted that the as-synthesized 
photocross-linked AuNPs have longer blood circulation time and shorter biological half-life 
than particle aggregates.63 Nevertheless, the penetration depth of 405 nm laser remains 
limited. In fact, for in vivo imaging application, the chosen NPs need to have the ability to be 
imaged at greater tissue penetration depth (including thick bone penetration for imaging of 
brain tumors, air-filled cavities for imaging of lung tumors, etc.), without compromising the 
spatial resolution.17,39,64 NIR shows better penetration depth in the tissue than visible light, 
yet, its clinical utility is still hindered due to auto-fluorescence, potential blink, scattering and 
photobleaching effects in various tissues.54,59 In fact, it is difficult to compare and evaluate 
the efficacy of different Au nanostructures in nanotheranostics, as their behavior is highly 
dependent on various parameters, such as size, shape and surface functional group.65 Au 
nanocages, with cubic shape, are particularly attractive as photothermal transducers for 
nanotherapeutics, owing to their interesting features such as flexible tuning of the localized 
surface plasmon resonance (LSPR) peaks to any wavelength of interest (in the range of 600-
1200 nm) and a large NIR absorption cross section (five orders of magnitude greater than the 
conventional organic dyes). With a compact size of about 40 nm, the hollow and porous 
structures of Au nanocages permit drug encapsulation with controlled release upon irradiation 
with NIR light.52 In another study, it was reported that cationic NPs exhibit superior cellular 
internalization, but inferior systemic circulation compared to their anionic and neutral 
counterparts 46. In view of this, the idea of integration of photothermal Au nanocages with 
zwitterionic stealth ligand has been proposed. As aforementioned, zwitterionic medication 
endows NPs with surface properties resistant to aggregation, binding plasma proteins and 
macrophage uptake, prolonging blood circulation time.59 Zwitterionic polymers coated on Au 
nanocages has successfully extended the NPs’ systemic circulation lifetime by 4-fold, without 
compromising its cellular internalization, breast tumor targeting ability and PTT efficacy. 
Sensitive to the changes in cell’s extracellular pH, the zwitterionic ligands on Au nanocages 
switch from “zwitterionic” at physiological pH (7.0-7.4) to “cationic” at acidic pH ( 6.5). 
Triggering of this charge reversal makes the NPs attach to the surface of cancer cells, leading 
to targeted accumulation within tumors.46  
Cervical cancer is the fourth most common cancer in women and has the fourth highest 
mortality rate (among cancers in women).66 Additionally, it is a solid tumor associated with 
human papillomavirus infection.66 An example of synergistic PTT and drug delivery for 
cervical cancer is the use of multi-layered single-walled carbon nanotubes, termed 
SWNT@BSA@Au-S-PEG-FA@DOX, which was prepared using a facile layer-by-layer 
assembly process.67 Carbon nanotubes display hemodynamic properties as its shape greatly 
affects its circulation time and biodistribution. 68 For example, the needle-like morphology of 
nanotubes contributes to increased specific area for interaction with plasma proteins and 
cells; permits cell penetration via both endocytosis and diffusion across the plasma 
membrane; and allows longer circulation time (up to 10 times longer) in blood, as compared 
to spherical nanomaterials.69 Coating of bovine serum albumin (BSA) on oxidized and cut-
single-walled carbon nanotubes (SWNTs) provides abundant active sites for the nucleation of 
Au seeds, subsequently converting Au into AuNPs by in situ reduction. Possessing ideal 
photothermal properties, the SWNT@BSA@Au was further modified with folic acid 
terminated-polyglycol (FA-PEG-SH), which endows the material with high water-
dispersibility, biocompatibility and selectivity towards human cervical cancer cells. 
Doxorubicin (DOX) was subsequently loaded onto the system, with a high loading ratio of up 
to 590 %. The resulting complex exhibited high efficacy, especially when combined with 
PPT (irradiation of the tumor with a 808 nm laser, 1 W/cm2 or 5 min, 24 h after systemic 
injection of the nanomedicine). Besides, release of DOX is induced by the pH value and 
temperature in the tumor microenvironment, adding selectivity to the system. The system 
completely eradicated tumors in vivo without systemic toxicity, as substantiated by several 
hematological and biochemical parameters and histopathological analysis.67 However, it is of 
utmost importance to note that the usage of high laser irradiance (1-48 W/cm2) is practically 
not applicable for clinical treatment of tumors, as they exceed the skin tolerance threshold 
values (maximum permissible exposure of skin at 808 nm is 350 mW/cm2, with an exposure 
time of 10-1000 s).70 Future studies can be focused on the interactions between SWNTs and 
actual biological environment such as blood, since the presence of protein corona in the 
biological fluids might affect the BSA coatings on SWNTs and subsequently modulate their 
biological fate.69  
Gold nanorod (AuNR) is an excellent photothermal agent owing to their adjustable 
longitudinal surface plasmon resonance and high light-to-heat conversion efficiency.71,72 
These rod-shaped NPs allow prolonged blood circulation time and facilitate deeper mammary 
tumors penetration than nanospheres with the same diameter.40,71 Dendrimers are inherent 
polymeric scaffolds for encapsulation of small inorganic NPs (2-20 nm) used to further 
increase blood circulation time, solubility and dimensional stability of nanohybrids.73 A smart 
nanohybrid, termed Au nanorod/dendrimer-assembly nanohybrids (AuNR@Da NHs), with 
size of about 130 nm, has been constructed by supramolecular encapsulation of 83.0 w/w% 
AuNR into dendrimer assemblies.73 The amphiphilic dendrimer assemblies are composed of 
PEGylated and antitumor adriamycin (ADR)-decorated dendrons, containing tumor 
microenvironmental matrix metalloproteinase (MMP)-cleavable linkages, intracellular GSH-
degradable disulfide bonds and pH-breakable hydrazone bonds that are highly responsive 
towards tumor microenvironment. Li et al. (2018)73 investigated the biological adapting 
ability of the nanohybrids under different biomimetic stimulations. The group proved that 
AuNR@Da NHs could adapt sequential biological barriers through triple-responsive features: 
enzyme/redox/pH, to facilitate deep tissue penetration and high internalization in tumors, 
particularly in human ovarian tumors that are deep within the abdominal cavity and most of 
the time difficult to palpate.74 The permeability of nanohybrids in ovarian tumors are further 
improved, credit to the efficient photothermal properties of AuNRs in AuNR@Da NHs 
(about 70 %, as compared to single AuNRs about 60 %). The amount of internalized AuNR 
and ADR mediated by nanohybrids, were about 27-fold and 6.6 times higher, respectively, 
than individual AuNR-treated. Furthermore, the nanohybrids were capable of generating 
hyperthermia (up to 67 C), with tumor accumulation of more than 2.3 times higher. NIR-
induced hyperthermia subsequently induces the rupture of the lysosome, accelerates the 
endosomal release of ADR/AuNRs and thus inhibits the human ovarian tumor cells in vivo. 
In brief, AuNR@DA NHs with laser irradiation offered strong curative effects, with an 
inhibition rate of 80.7 %, on synergistic chemo-photothermal treatment for combating 
multidrug resistance.73  
Overall, targeting and therapeutic efficacy of Au nanostructures can be enhanced by tuning 
its physiochemical properties such as size, surface chemistry and shape. On the other hand, 
tumor pathological characteristics also play an important role in penetration of 
nanomedicines in tumor, as tumor microenvironment is highly heterogeneous between 
different types of tumors. Hence, characterization of both Au nanostructures and pathological 
properties of tumors are equally important in the design of nanomedicine with 
nanotheranostic properties.  
Other nanomaterials 
Inorganic nanomaterials are multifunctional NPs platform synthesized from metals, metal 
oxides and metal sulfides. Inorganic nanomaterials are relatively stable over large ranges of 
pH and temperature,10 resistant to enzymatic or photochemical degradation,70 thus suitable 
for nanotheranostics in tumor microenvironment.70,75  
Copper sulfide (CuS) NPs are featured with several properties compared to other commonly 
used NPs, such as prominent absorbance, effective heat conversion, small particle size, easy 
modification and facile synthesis.76 A tumor-targeting nanocomposite (CuS@BSA-MBA-
cRGD) with photothermal effect for targeting of liver-intestinal metabolism pathway was 
synthesized recently.77 The biocompatibility and stability of CuS NPs were improved via 
capping effect of BSA. Then, NIR fluorescence probe (MBA) and tumor-targeting ligand 
cyclic arginine-glycine-aspartic acid (cRGD) peptide were further conjugated on the surface 
of CuS@BSA. Peptides are another commonly used ligand targeting moiety, with advantages 
in terms of chemical stability, ease of synthesis and reduced immunogenicity.59 cRGD can 
target the cell-adhesion molecule, αvβ3 integrin, that is over-expressed on tumor new-blood 
vessels and some tumor cells.78 The as-synthesized CuS@BSA-MBA-cRGD served as an 
infrared thermal imaging contrast agent for infrared thermal imaging and as a photothermal 
agent for tumor ablation via PTT. However, the obtained nanocomposite has a mean diameter 
of about 51.2 nm,77 raising concerns regarding its uptake by reticuloendothelial system (RES) 
organs that may cause slower elimination from the body and potential toxicity after effective 
treatment.79  
Generally, most of the nanomaterial-based PDT requires an additional photosensitizer or 
high-power laser sources for effective therapy. However, the high concentration of NPs and 
laser irradiation with long irradiation time may lead to a heat generation during NIR therapy. 
The rise in temperature will subsequently lead to cell death rather than ROS generation for 
PDT. Srivani et al. (2018)70 proposed copper bismuth sulfide (Cu3BiS3) nanocrystals as an 
innovative human breast tumor treatment alternative, after showing the potential of Cu3BiS3 
inducing PDT without any photosensitizer, at safe laser zone (808 nm, 10 mW/cm2, 10 min), 
and in the deep tissue penetrative NIR region. Bi, with high x-ray attenuation, could serve as 
an efficient x-ray contrast probe; while Cu ions, with broad NIR absorption, could serve as 
NIR-responsive PDT and PTT agents. Upregulation of Cu ion leaching upon irradiation 
coupled with Bi efficiently capturing more photons is believed to contribute to the realization 
of Cu3BiS3 in exceptional PDT effects at low laser power.
70 Although the group has shown 
that the as-synthesized Cu3BiS3 nanocrystals are highly biocompatible without any genotoxic 
effects, yet, the uptake of this 12 nm nanocrystals by RES organs, their in vivo degradation 
behavior and clearance after PDT still require further investigation. Besides, the influence of 
Cu3BiS3 nanocrystals on the biogenesis and activity of cellular organelles require further 
understanding as organelle dysfunctions will lead to dramatic consequences on human health.  
A photosensitiser-Pd@Pt nanosystem has been designed for highly efficient PDT in human 
breast tumors [see Figure 2b (ii)].44 Palladium (Pd)-based nanomaterials have good catalase-
like activity, which can decompose H2O2 to produce oxygen and water. This subsequently 
improves the hypoxic environment of solid tumor.44 However, like other inorganic 
nanomaterials, Pd has chemically/biologically inert framework, which raises concerns over 
the low biodegradation and biosafety issues.10 Functional inorganic 2D biomaterials, MnO2 
nanosheets, have been introduced recently for improved theranostic performance [see Figure 
2b (iv)].80 Preliminary studies demonstrate its biocompatibility as Manganese (Mn) is one of 
the necessary trace elements in the human body. The ultra-thin MnO2 nanosheets structure, 
with an average thickness of 2 nm, is highly sensitive towards the endogenous (acidic and 
reducing) tumor microenvironment.80 It was found that the MnO2 nanosheets started to 
disintegrate and release Mn2+ only within 3 min in acidic (pH 5.0) and reducing ([GSH] = 5.0 
mM) solutions, with longitudinal relaxitivity (r1) of 5.45 mM
-1s-1 and 4.81 mM-1s-1, 
respectively. The r1 of MnO2 nanosheets in neutral solution was only 0.87 mM
-1s-1. High 
values of r1 coupled with various direct photographic images demonstrated the potential of 
MnO2 nanosheets structure as the contrast agents for MRI, since the higher accessibility of 
the released Mn2+ to water molecules could enhance brightening effect of MRI signal. MnO2 
nanosheets also possess high intrinsic photothermal-conversion capability for PTT. 
Furthermore, surface modification of the MnO2 nanosheets with soybean phospholipid 
improved the stability of the nanosheets in physiological condition.80 Mesoporous NiO 
(mNiO) NPs also appear as a photothermal conversion agent for cancer PTT [see Figure 2b 
(iii)].81 Artemisinin (ART) is a traditional Chinese medicine that is believed to inhibit tumor 
growth. Attachment of mNiO NPs and terbium complexes bestow mNiO with luminescence 
imaging features. The mNiO-Tb serves as a MRI contrast agent, a luminescence imaging 
probe and a vehicle for ART. Synergistic PTT and radical-induced therapy of cervical tumors 
was achieved using this ART-loaded mNiO nanoplatform.81 Nonetheless, the selective 
damage mechanism of ART to cancer cells remains elusive, and the toxicity of ART 
derivatives to normal cells needs to be explored.  
Perfluorocarbon (PFC) is a chemically inert molecule with high oxygen-carrying capacity 
and good biocompatibility for in vivo application.47 Owing to the intrinsic hydrophobic nature 
of the PFC compounds, their clinical application usually involves encapsulation by a carrier 
matrix. Porous hollow magnetic Fe3O4 NPs (PHMNPs) have a large central cavity for the 
loading of small molecules and/or the therapeutic cargo, while retaining favorable biological 
properties of conventional iron oxide NPs (intrinsically super-paramagnetic, as a contrast 
agent for MRI). In view of this, PFC and etoposide (EP) were loaded onto PHMNPs. Oxygen 
was released at a moderate rate from the PHMNPs over an extended period of time, 
effectively reducing the hypoxia-induced EP resistance of liver tumor cells and facilitating 
concurrent chemotherapy. Modification of the surface of PHMNPs with lactobionic acid 
(LA)-containing amphiphilic polymers (LA-PEG-S-S-C18PMH), through hydrophobic 
interaction, facilitates selective targeting of LA against the asialoglycoprotein receptor 
present on the plasma membrane of hepatocytes.47 Besides, the intracellular agglomeration of 
the nanocarriers after GSH-triggered removal of the hydrophilic LA-PEG segment could 
significantly enhance intracellular accumulation and improve therapeutic efficacy.47 
In addition, the upconversion NPs (UCNP)-based theranostic micelles have been proposed 
for dual-modality imaging and PDT in HCC [see Figure 2b (i)].82 Loading of mitoxantrone 
(MX) and anti-epithelial cell adhesion molecule (anti-EpCAM) onto PEGylated UCNP 
micelles has improved the biocompatibility and synergistic antitumor efficiency of the 
system, without any noticeable systemic toxicity.82 Like other commonly used UCNP-based 
therapeutic approach, the as-synthesized 23.4 nm UCNPs are difficult to fabricate in ultra-
small (< 15 nm diameter) sizes. The quantum yield of these UCNPs was not reported. 
Besides, since water has an absorption peak around 980 nm, laser excitation at 980 nm will 
result in unnecessary tissue heating during PDT. It is of interest to develop UCNPs which can 
be excited by other NIR wavelengths and allow deeper tissue penetration. Lastly, overall 
understanding of nanotoxicology of UCNPs (NPs distribution, excretion, metabolism, 
pharmacokinetics etc.) in animal models is of utmost importance.83  
Quantum dots (QDs) is a luminescent inorganic nanomaterial with rich surface chemistry and 
optical properties. The application of QDs in biomedical field has been challenged by its non-
specific internalization and toxicity.84 Shi et al. (2018)84 covalently coupled folic acid (FA) 
and 5-fluorouracil acetic acid (FUA) on the surface of QDs, to produce a HCC targeted 
therapy system, named FA-QDs-FUA. FA is responsible for the specific targeting of the 
system to the hepatocarcinoma cells; while QDs acts as the delivery vehicles and imaging 
agent. FUA which interferes with nucleic acid synthesis, has been chosen as the therapeutic 
agent. PEG has been selected as the linker chain to facilitate attachment of FUA to the QDs’ 
surface and dramatically suppress the non-specific interaction of QDs. The optimal 
proportion of FA: PEG-QDs: FUA = 10: 1: 100 was used. Noteworthy, the content of FA in 
the system is controlled within 10 %, since excess FA may promote undesired tumor cell 
growth. The system was observed to exert reduced toxic side effects and better anti-tumor 
efficacy.84 Nevertheless, the particle size of FA-QDs-FUA was about 220.28 nm, which is 
bigger than 160 nm, raising concerns about the cellular uptake and accumulation of the FA-
QDs-FUA at tumor sites. Another similar work has been reported by Ma et al. (2018).85 The 
group coupled second near-infrared window fluorescent (NIR-II) Ag2Se QDs with 
gadopentetate dimeglumine injection (Gd-DTPA) for dual-modality: T1-weighted MRI and 
fluorescence imaging. The excellent temporal resolution and high tissue penetration depth 
were achieved by fluorescence imaging, further supporting the potential of QDs as 
multifunctional contrast agents for multimodal imaging in clinical diagnosis.85 
Magnetic metal oxide nanomaterials (MMONPs) are negative contrast agents for T2-weighted 
MRI. In response to intratumoral oxidability and acidity, MMONPs degrade and release 
corresponding metal ions that can serve as highly efficient positive T1-weighted contrast 
agent. The ratio of increase of T1 signals against decrease of T2 signals (T1/ T2) from 
MMONPs, is known as ratiometric MRI, which is highly selective for solid tumor imaging.45 
Cobalt oxide nanoprism (Co3O4), a type of MMONPs, has been selected and tuned for 
selective ratiometric MRI tumor imaging and synergistic cancer theranostics (PTT, 
chemodynamic and chemotherapy). The as-prepared Co3O4 nanoprism is cuboidal, with a 
thickness of 3.26 nm and a length of 33.29 nm, instead of triangular structure. This could be 
due to the presence of high concentration of surfactant used during the synthesis which 
subsequently inhibited nanomaterial growth in specific spatial directions.45 It is interesting to 
note that although the sharp vertices of the triangular nanoprism may lead to stronger near-
field enhancements for plasmonic applications, unfortunately, its high surface energy vertices 
most likely will make the nanoprism highly unstable and readily degradable.86 Nevertheless, 
the Co3O4 nanoprism possess significant photothermal conversion efficiency (= 60.07 %), 
outstanding MRI contrast (r2= 5.42 mM
-1s-1) and good DOX delivery (29.36 mg/g), with a 
low detection limit (50 nM) and broad linear range (0-50 M).45 In turn, the cuboidal 
structure and fast degradation property of the as-prepared Co3O4 nanoprism could contribute 
to enhanced drug delivery and controllable drug release.  
Radiotherapy is another major modality of cancer therapy. However, radio-resistance, one of 
the intrinsic features of solid tumors, often gives rise to unsatisfactory therapeutic outcome 
and subsequent tumor relapse.13,43 Du et al. (2017)87 constructed a multifunctional theranostic 
agent, with a mean diameter of 15 nm, integrating radiation therapy with high-depth PTT. 
Functionalization of amphiphilic D-α-tocopherol PEG 1000 succinate (TPGS-Cu3BiS3) with 
bimetallic chalcogenide nanocrystals (NCs) increased the deposition of X-ray irradiation 
energy within cancer cells and triggered radiation damage in vivo. Moreover, conversion of 
NIR light (1064 nm) into heat greatly improved tumor oxygenation via increasing the blood 
flow, overcoming the hypoxia-associated radio-resistance of the tumor. The presence of 
copper ions is capable of catalyzing the conversion of endogenic H2O2 into highly reactive 
hydroxyl radicals and increase the level of oxygen radicals, hence further destroy the cancer 
cells. The as-synthesized NCs also have strong absorption in the second NIR window (1000-
1400 nm), allowing a deeper tissue penetration ability, with low scattering and energy 
absorption by tissues, than in the first NIR window (650-950 nm).87 High atomic number NPs 
such as platinum, gold and bismuth are high electron emitters. These elements can act as 
radiosensitizers and amplify the effects of radiation.88 Bismuth heteropolytungstate (BiP5W30) 
nanoclusters have also been explored as radiosensitizers for radiotherapy enhancement.43 
Owing to the electron structure and multi-electron property, BiP5W30 nanoclusters deplete 
GSH via redox reaction, catalyze the decomposition of H2O2 to HO (about 1.3-fold) to 
enhance ROS generation upon x-ray radiation. The coupling of BiP5W30 nanoclusters with 
reduced graphene oxide (rGO) formed a heterostructure that not only promotes electron-hole 
separation to improve radio-catalytic activity (about 4-fold) but also improves the oxygen 
level within tumors since rGO can promote mild photothermal effect.43  
Overall, inorganic nanomaterials serve as a platform for biomedicine, yet the often-neglected 
characterization and fairly weak fundamental understanding of its structure-function 
correlations often limits its predictive capabilities in nanotheranostics.  
 
Figure 2 Brief overview of nanomaterials used for solid tumor theranostics, with their 
respective TEM images. (a) Gold nanoclusters (i) The photocross-linkable Au 
nanoparticles for photothermal therapy and photoacoustic imaging of tumors in vivo. 
Adapted with permission from ref 42. Copyright 2019 Ivyspring International Publisher. 
(ii) Preparation of the smart Cu (II)-aptamer complexes based gold nanoplatform for 
synergistic PDT/PTT/chemotherapy of hepatocellular carcinoma. Adapted with 
permission from ref 41. Copyright 2017 Ivyspring International Publisher. (b) Inorganic 
nanomaterials (i) The structure of PEGylated upconversion-based micelles which 
permits dual-modality magnetic resonance/upconversion luminescence-guided 
synergistic chemotherapy and photodynamic therapy in hepatocellular carcinoma. 
Adapted with permission from ref 82. Copyright 2018 Royal Society of Chemistry. (ii) A 
photosensitizer-Pd@Pt nanosystem (Pd@Pt-PEG-Ce6) in enhancement of tumor-
specific photodynamic therapy. Adapted with permission from ref 44. Copyright 2018 
John Wiley and Sons. (iii) The artemisinin-loaded mesoporous nanoplatform for 
synergistic photothermal and radical-induced tumor theranostics. Adapted with 
permission from ref 81. Copyright 2018 American Chemical Society. (iv) Overview of 2D 
ultrathin MnO2 nanosheets in magnetic resonance imaging and ultrasensitive stimuli-
responsive photothermal therapy. Adapted with permission from ref 80. Copyright 2018 
Elsevier.  
Polymeric nanoparticles 
Polymeric NPs is a collective term given for any type of polymer NPs, but specifically for 
nanospheres and nanocapsules built from synthetic polymers (e.g. poly(organophosphazene) 
(POP), poly(ethylene glycol) (PEG), etc.) or natural polymers (e.g. chitosan, gelatin, etc.).10 
The highly electron-delocalized structures, excellent light-harvesting and light amplifying 
properties, versatile surface modification, excellent photostability and biocompatibility of 
polymeric NPs contribute to their rapid advancements in solid tumor theranostics. Besides, 
with the size range between 10-1000 nm, polymeric NPs have proven to be viable carriers of 
therapeutic agents.  
Encapsulation of methotrexate (MTX), a chemotherapeutic agent, in polymeric NPs is crucial 
in controlling its toxicity and side effects.89 Two different block copolymers (poly(ethylene 
glycol)-b-poly(glutamic acid)-b-poly(ethylene glycol) (GEG) and poly(ethylene glycol)-b-
poly(glutamic acid) (EG) conjugated with FA have been designed and used to encapsulate 
MTX. Both NPs, named M-GEG and M-EGFA NPs, are employed for passive and active 
targeting of cervical carcinoma, respectively [see Figure 3a (ii)].89 FA has been used as a 
homing device to actively target and direct M-EGFA NPs towards the tumor, facilitating 
targeted drug release at the tumor site. On the other hand, M-GEG NPs passively target and 
accumulate at the cancer cells, by exploiting the EPR effect. Subsequently, M-GEG NPs 
release MTX inside the cytoplasm at a controlled rate to induce cell apoptosis. This 
mechanism of M-GEG NPs allowed long-term cytotoxicity action on the tumor cells while 
minimizing side effect to healthy tissues.89 The entrapment efficiency for both polymeric NPs 
was found to be about 93-96 %, with drug-loading content of about 38-47 %. Both polymeric 
NPs have improved the systemic circulation and intracellular delivery of MTX. The potential 
of these polymeric NPs as alternative to conventional chemotherapy for human cervical 
carcinoma are supported by their complete biological evaluation in terms of cytotoxicity, 
intracellular drug uptake and release, as well as induction of apoptosis.89 Future research can 
be expected on fabrication of stimuli-responsive block copolymers, for specific targeting and 
precise control of the drug-release and versatility in clinical applications.  
On the other hand, poly(ethylene glycol)-b-poly(ɛ-caprolactone) (PEG-PCL) is a 
biodegradable and biocompatible block polymer.90 PEGylation delays renal filtration, 
prolongs plasma circulation and reduces non-specific uptake of nanomaterials by 
macrophages.18,19,91 Encapsulation of silicon naphthalocyanine (SiNc), a photostable 
fluorescence molecule, within the hydrophobic core of the PEG-PCL NPs serves as a real-
time activatable theranostic nanoplatform [see Figure 3a (i)].90 The as-synthesized nanoprobe 
is predominantly fluorescent at tumor/cancer site (quantum yield at about 11.8 %). This is 
mainly because the poor water soluble SiNc (<1 ng/mL) in the PEG-PCL NPs tend to 
aggregate in aqueous environment and lead to fluorescence self-quenching. However, once 
SiNc infiltrated into the core of the solid tumor, the complex acidic intracellular environment 
(pH 6.5-6.8) and the interior of the endosome/lysosome (pH 4.5-6.5) will disrupt the 
structural integrity, trigger the leaching of SiNc from the nanoprobe, leading to NIR 
fluorescence recovery.90 The nanoprobe reveals high cancer-to-normal tissue contrast ratio 
(about 1.6-1.9-fold) specifically at the tumor sites, and with none or minimal fluorescence 
signal in healthy organs.90 This highly sensitive fluorescence switching nanoplatform 
successfully broaden the imaging and treatment window, making it highly promising for 
further clinical studies. The group also validated that heat can be efficiently generated by the 
nanoprobe up to 12 mm deep within tumors from the point of NIR light (1.3 W/cm2) for PTT, 
which is beneficial for nanotheranostics of ovarian cancer which usually started in one or 
both ovaries or fallopian tubes located in the female pelvis. Moreover, the chemistry involved 
in the SiNc-mediated combinatorial phototherapy can be easily tailored via photo irradiation 
dosage.90 On the other hand, self-assembly of PEG-PCL with folate-PEG-cholesterol micelles 
forms a spherical and self-luminescing nanosystem (called POCL nanoreactor) with a 
diameter of about 50 nm.92 POCL encapsulates bis[3,4,6-trichloro-2-(pentyloxycarbonyl) 
phenyl]oxalate (CPPO, a chemical power source with high reactivity to H2O2), poly[(9,9’-
dioctyl-2,7-divinylene-fluorenylene)-alt-2-methoxy-5-(2-ethyl-hexyloxy)-1,4-phenylene] 
(PFPV, a chemiluminescence converter), and tetraphenylporphyrin (TPP, a photosensitizer 
with NIR emission and singlet oxygen. The folate ligand on the POCL surface allows specific 
targeting at the tumor site. Upon trigger by the high level of H2O2 at the tumor site (10
-6 M, 
normal condition = 10-7 M), POCL can be used for chemiluminescence imaging and PDT via 
a series of intraparticle relayed resonance energy transfer. The tumor cells are converted to a 
“light on” state and subsequently destroyed by the generated singlet oxygen. With such an 
excellent NIR light emission and singlet oxygen generation abilities, POCL showed a high 
image contrast in fluorescence imaging with a high antitumor effect and low systemic 
toxicity.92  
Ursolic acid (UA), a pentacyclic triterpenoid extracted from Hedyotis diffusa Willd, has 
shown great potential in cancer therapy but their efficacy is extremely hindered by limited 
water solubility and poor pharmacokinetics in vivo. Yan et al. (2018)93 has employed cationic 
nanomicelles derived from pluronic F127 as a delivery vehicle of UA for colorectal cancer 
treatment. Pluronic F127 is a widely-used biocompatible polymeric drug delivery vehicle, 
comprising of polyethylene oxide–poly-propylene oxide–polyethylene oxide (PEO–PPO–
PEO) chains. The PPO segment of pluronic F127 allows incorporation of lipophilic drugs 
while hydrophilic segment of F127 prevents adsorption and aggregation with other bio-
macromolecules. Since the positively charged NPs have stronger affinity with negatively 
charged cell membranes, therefore, cationic polymer of stearoyl chloride grafted 
polyethylenimine copolymer (C18-PEI) was functionalized to increase UA uptake by 
colorectal cancer cells.93 This UA loaded cationic nanomicelles, termed as FUP, was 
fabricated through simple self-assembly of UA, F127 and C18-PEI in ethyl alcohol. FUP can 
effectively block colorectal cancer cell proliferation by interfering cell cycle arrest at the G1 
checkpoint and induce cell apoptosis mechanism.93 Nonetheless, further studies on the 
degradation behavior and clearance of NPs after performing therapy are necessary.  
Photoacoustic imaging (PAI) is a biomedical imaging modality combining the high contrast 
of optical imaging with the high spatial resolution of ultrasound imaging.5,42,45,72 PAI can also 
be defined as the non-radiative conversion of light energy into sound energy.17 Based on the 
use of non-ionizing laser pulses, PAI non-invasively visualizes anatomical structures with 
greater penetration depth (several cms) and specificity than conventional optical imaging, 
suitable for imaging superficial tumors at breast and skin.94 On the other hand, high intensity 
focused ultrasound (HIFU) is a minimally invasive therapeutic modality. HIFU concentrates 
multiple intersecting beams of ultrasound into the targeted tumor region. Subsequently, it 
generates hyperthermia and mechanical effects to destroy the affected areas.95 A 
multifunctional poly(lactic-co-glycolic acid) (PLGA) nanocapsule, termed Cu2-
xS/PFBO@PLGA or in short CPPNs, encapsulating PAI contrast copper sulfide nanodots 
(Cu2-xS NDs) and a typical HIFU synergistic liquid, perfluorooctyl bromide (PFOB) has been 
constructed using emulsion solvent evaporation strategy.95 The high performance of Cu2-xS 
NDs in the absorption and conversion of NIR confers high PAI contrast capability to the 
CPPNs, by which the location of the CPPNs within a tumor can be monitored successfully 
under PAI. Shifting absorption from the first to the second NIR-window could enhance PAI 
contrast in imaging of deep lying living structures in vivo.17 Due to the encapsulated PFOB, 
the cavitation effect in CPPNs is improved, thus enhances the ablation efficacy under HIFU 
exposure. With a particle size of 123.7 nm, CPPNs show its potential as a theranostic agent 
for future photoacoustic image-guided HIFU synergistic therapy of breast cancer.95 However, 
high level of ultrasound energy (usually more than 100 W/cm2) may cause damages to 
healthy tissues, especially along the path of ultrasound propagation, hence leading to severe 
side effects.96  
Aggregation-induced emission (AIE) is a concept originated from the phenomena that a class 
of fluorogens are non-emissive as free molecules but luminescent as aggregates.57,97 AIE-
based bioprobes are suitable to use in real-time imaging probes, credit to their low 
background, high sensitivity and resistance to photobleaching. A smart nano delivery system, 
named STD nano-micelle (STD-NM), with ST and TD peptide functionalization and AIE 
“switch on” characteristics has been presented for precise theranostics and apoptosis 
monitoring of colon cancer.97 Comprising of pH-triggered targeting peptide STP (sequence: 
SKDEEWHKNNFPLSPG), a caspase-3 responsive peptide linker (sequence: DEVD) and an 
AIE molecule tetraphenylethylene (TPE), ST could recover the fluorescence of the 
nanocarrier during apoptosis. Meanwhile, TD, a tumor acidity-activated peptide made up of 
the cell-penetrating peptides TAT and 2,3-dimethylmaleic anhydride, maintained the 
“stealth” stability of the nanocarrier in the physiological environment.97 Upon exposure to 
tumor microenvironment, STP and TAT were switchably stimulated and activate the peptides 
to penetrate through the colon cancer cells and subsequently release the anticancer drugs (cis-
platinum and DOX) into the tumors. The AIE signal will then be “switched on”. Gene 
analysis by RNA-seq has also been performed, supporting the superior therapeutic effect of 
anticancer drugs-loaded STD-NM treatment. 97  
Generally, poor spatial resolution, shallow tissue penetration and relatively low quantum 
yield of NIR-emissive polymeric NPs than other common fluorescent imaging probes are 
some of the concerns for polymeric NPs in theranostics. The interaction between light-
induced charge transfer of polymeric NPs with other biological activities requires further 
detailed study. 
Lipid nanoparticles 
Solid lipid NPs are made up of rigid core of hydrophobic lipids surrounded by a monolayer of 
phospholipids. This structure improves their biocompatibility and stability in biological 
environment, making them suitable as a carrier system.98  
A multifunctional hypoxia-responsive theranostic liposome co-encapsulating a 
photosensitizer Ce6, hypoxia-activated prodrug tirapazamine (TPZ) and gene probe miRNA-
155 was designed for synergistic PDT-chemotherapy of breast cancer.99 The liposome was 
fabricated using an innovative hypoxia-responsive 2-nitroimidazole derivative conjugated 
PEG amphoteric polymer. The gene probe is a molecular beacon probe with the loop 
sequence complementary to the target miRNA-155. In absence of target, the fluorescence of 
the gene probe is switched off; upon hybridization with the target, the fluorescence is 
switched on, and effectively used for detection and diagnosis of intracellular oncogenic 
miRNA biomarker in breast cancer.99 Subsequent laser irradiation (670 nm, 0.48 W/cm2, 10 
min) induced Ce6-mediated PDT by consuming oxygen to generate intracellular ROS, such 
as singlet oxygen, which causes severe hypoxia. The PDT-induced hypoxia led to the 
disassembly of the liposome, intracellular TPZ leakage to cell nucleus and induce DNA 
damage and cell apoptosis.99 A detailed nanotoxicology study of the as-produced liposome 
system is imperative for possible clinical application as TPZ is currently under Phase III 
clinical trial.  
An ultrasound molecular probe based on lipid NPs has been introduced for precision 
theranostics at an early stage of HCC [see Figure 3b (i)].100 As common lipid NPs lack of 
specific targeting ability, hyaluronic acid (HA) has been chosen as a ligand to actively target 
the overexpressed CD44 cell adhesion factor on HCC. Cysteine-flanked cell-penetrating 
peptide (CPP), CG-TAT-GC, has been selected to improve the delivery of macromolecular 
substances into the nucleus without causing cytotoxicity.100 The as-synthesized lipid NPs is 
known as HA-mediated cell penetrating peptide-modified with 10-hydroxycamptothecin-
loaded on a phase-transformation lipid NPs (HA/CPPs-10-HCPT-NPs). Upon trigger by low-
intensity focused ultrasound (LIFU) sonication, the NPs in tumor tissue and cells undergo 
acoustic droplet vaporization (ADV) and are transformed into microbubbles.100 The resultant 
microbubbles not only able to provide significant contrast enhancement in tumor-site 
imaging, but also increase permeability of NPs into tumor blood vessels and cell membrane.96 
Since the acoustic intensity of LIFU sonication is usually low, no more than 3.2 W/cm2, it is 
less likely to cause tissue necrosis as compared to HIFU.96 This fascinating mechanism 
successfully induces local release of antitumor drug in the cytoplasm and nucleus.100 
However, there are some concerns with this approach. Although the ligand-mediated active 
targeting has been used to improve the targeting efficiency, it is important to fully understand 
and avoid the adverse side-effects due to off-target distribution of the CPP and its cargo 
which might induce mutations, cytotoxicity or initiate immune responses in the host. 
Secondly, the pharmacokinetics, stability and circulation time of the system in bloodstream 
should also be further investigated. In addition, since the effect of ultrasound is highly 
localized, their applicability in tumor metastasis is highly compromised. 
On the other hand, abnormal levels of H2O2 (about 50-100 µM) often correlate with 
physiological and pathological conditions like inflammation and cancers. Generally, the 
concentration of H2O2 in physiological environments should be below 50 µM.
101 Liposomal 
nanoprobe loaded with horseradish peroxidase (HRP) and its substrate, 2,2-azino-bis(3-
ethylbenzothiazoline-6-sulfonic acid) (ABTS), has been presented for in vivo detection of 
inflammation, photoacoustic detection and imaging of H2O2 (down to sub/micro molar 
concentrations) [see Figure 3b (ii)].101 In the presence of endogenous H2O2, HRP loaded in 
liposomes would catalyze ABTS (colorless) into its oxidized form (greenish) and show strong 
NIR absorbance (700-900 nm), allowing sensitive PAI of early stage tumors (as small as 2 
mm in size). Meanwhile, based on the difference in H2O2 contents, the nanoprobe also allows 
diagnosis and imaging of LPS- (a lipoglycan that triggers inflammation) and bacteria-induced 
inflammation, orthotopic brain tumors, breast tumors and metastatic tumors. Besides, this 
spherical shape liposomal NPs with an average diameter of about 100 nm concurrently 
achieve selective PTT of tumors with high efficacy and minimal non-specific heating damage 
to surrounding normal tissues.101 However, the loading capacity of ABTS and HRP were 
found to be limited at about 23.17 and 5 %, respectively. This could be due to premature 
release of the drug from the lipid matrix as changes in temperature during administration may 
cause polymorphic transitions of the lipid matrix.10 The depth-dependent light attenuation and 
interference of unwanted background signals remain challenges for the clinical application of 
PAI.  
Superparamagnetic iron oxide nanoparticles-loaded solid lipid (SPIONs) is made from iron, 
one of the most abundant metals present in metabolism. SPIONs have big potential as 
theranostic agent as they display interesting cellular and in vivo interactions with no dramatic 
toxicity.69,102,103 A smart nanovehicle with DOX and SPIONs delivery system, in short 
DOX/SPIONs-loaded DFSLNs, has been constructed for oral chemo/magnetothermal 
combination therapy of colon cancer.98 Despite the system combined both DOX 
chemotherapy and hyperthermia therapy (generated from SPIONs) with high frequency 
magnetic field (HFMF), its therapeutic efficacy is still limited by the systemic drug 
absorption into blood circulation. Thereby, the group innovatively coated folate (FA) and 
dextran on the surface of the NPs in a sequential layer-by-layer manner.98 Although the 
fabrication of SPIONs can be relatively easy and reproducible, biocompatible polymer layer, 
such as PEG and polyvinyl alcohol (PVA), is normally coated on the SPIONs surface to 
improve their biocompatibility and stealthiness for specific targeting. This is because naked 
SPIONs tend to sediment and aggregate at physiological conditions, resulting in an increased 
risk of toxicity.69 Coating of the polysaccharide dextran shell layer on the NPs surface not 
only evaded the cellular transport and systemic absorption by at least 2 folds, but also 
enhanced the particle accumulation at the tumor sites by specific association with dextranase 
present only in colon. The subsequent enzymatic degradation and removal of dextran coating 
led to the exposure of the FA residues that further facilitate cellular level targeting and uptake 
of the system by receptor-mediated endocytosis. The preliminary results demonstrated 
prominent therapeutic efficacy (a 15-fold decrease in tumor mass of mice than the PBS 
control) of DOX/SPIONs-loaded DFSLNs for the oral administration, with no apparent 
systemic side effects or toxicity.98 The particle size of DOX/SPIONs-loaded DFSLNs is 
approximately 132 nm. In fact, the optimal size of the nanomaterials designed for colorectal 
cancer should be between 10-100 nm in order to avoid triggering of immune response and 
clearance by glomerular filtration in the kidneys.104 The spherical shape of the nanomaterials 
would encourage longer circulation time in blood and faster uptake by colorectal cancer 
cells.105  
In short, the potential side effects arising from the off-target distribution of the molecular or 
drug-loaded lipid NPs require more studies for validation on the effectiveness of the delivery 
system. The pharmacokinetics, stability and circulation time of the nanomedicine in the 
bloodstream should also be further investigated.  
  
Figure 3 Brief overview of nanomaterials used for solid tumor theranostics, with their 
respective TEM images. (a) Polymeric nanoparticles (i) Illustration of a tumor-
activatable silicon naphthalocyanine (SiNc) encapsulated in a copolymer, PEG-PCL 
nanoparticles, that permits NIR fluorescence-guided surgery and combinatorial 
phototherapy of ovarian cancer tumors. Adapted with permission from ref 90. 
Copyright 2018 Ivyspring International Publisher. (ii) Overview of block copolymer 
(PEG and PGA) based nanoparticles in passive and active theranostic intervention of 
cervical cancer. Adapted with permission from ref 89. Copyright 2017 American 
Chemical Society. (b) Lipid nanoparticles (i) A multifunctional ultrasound molecular 
probe (cell-penetrating peptide-modified targeted drug-loaded phase-transformation 
lipid nanoparticles) with low-intensity focused ultrasound in hepatocellular carcinoma. 
Adapted with permission from ref 100. Copyright 2018 Ivyspring International 
Publisher. (ii) A H2O2-responsive liposomal nanoprobe capable for photoacoustic 
inflammation imaging and photothermal therapy of early-stage of small tumors and 
metastatic lymph nodes. Adapted with permission from ref 101. Copyright 2017 PNAS. 
Graphene  
Graphene and its derivatives have become the spotlight of nanotheranostics since the last 
decade, owing to their electrically tunable surface chemistry and mechanical 
robustness.102,106–108 The sp2-hybridised carbon atoms in a honeycomb network provide 
graphene with a large surface area, enabling the compounds to adsorb/functionalize on both 
sides of its planar surface. Moreover, the large molecular weight of graphene oxide (GO) 
enhances the imaging contrast,109 while its electrical properties allow long-range fluorescence 
resonance energy transfer (FRET).110 GO presented low uptake in the RES and long blood 
circulation time at 1 mg/kg body weight within days.111  
Melanoma is a form of skin cancer caused by excessive exposure to the sun’s ultraviolet 
radiation.112,113 A work using only GO (without the co-presence of any photosensitizers) to 
sensitize the formation of singlet oxygen for dual nanomaterial-mediated PDT and PTT of 
solid melanoma tumors was reported in 2016.114 The group proved that the nano-sized 
graphene is suitable for in vivo fluorescence imaging operated using inexpensive laser setups. 
GO is able to absorb NIR light that subsequently induces the generation of singlet oxygen 
and offers deeper tissue penetration depths.114  
However, the relatively hydrophobic nature of graphene makes it difficult to be taken up by 
cells, which in turn minimize their therapeutic efficacy. Hwang et al. (2016)110 has therefore 
suggested to graft a biopolymer of HA and a CD44 receptor-specific polysaccharide, onto the 
GO surface (see Figure 4a).110 The as-synthesized 170 nm HA-GO conjugate improved 
stability and solubility of GO in ionic solutions, without any aggregation. With such an idea, 
the group has also successfully developed an interesting fluorescence-switchable theranostic 
platform that is able to sense oncogenic miR-21 using anti-sense miR-21 peptide nucleic acid 
probes and show therapeutic effect on breast cancer simultaneously.110 On the other hand, 
GO/gold nanorods (GO/GNR) theranostic nanohybrids have been synthesized in situ at room 
temperature for precise tumor computed tomography (CT) imaging and PTT of pancreatic 
cancer.115 GO is chosen as the template for the synthesis of GNR due to the presence of many 
oxygen-containing functional groups which can improve solubility and biocompatibility of 
the system.115 Meanwhile, the synthesis method is straightforward, environmental-friendly, 
highly adaptable for different types of synthesis of GO/NPs and most importantly does not 
form any aggregates. The GO/GNRs showed photothermal effect in vitro, with good optical 
morphological stability up to six cycles of 808 nm laser irradiation.115  
Graphene quantum dot (GQD) is a zero-dimensional carbon material with excellent chemical 
stability, optical and electronic properties, biocompatible and allow easy surface 
modifications.116,117 Besides, GQD can produce ROS with significantly high quantum yield 
(greater than 1.0) for PDT, due to their excellent electron donating and accepting 
capability.118 GQD has the property of extremely high intrinsic mobility of charge carriers.119 
The work of loading IR780 iodide (IR780) onto FA-functionalized GQD via π-π stacking 
interactions has been reported recently.119 The GQDs-FA contains a large and intact sp2 
domain with carboxyl groups around the edge which exhibits excellent water solubility and 
suitable for further conjugation (see Figure 4b).119 IR780 is an effective theranostic agent for 
simultaneous NIR fluorescence imaging and PTT. Yet, its application is often hampered by 
its insolubility in different solvents due to the presence of the rigid chlorocyclohexenyl ring 
in the structure. Interestingly, the water solubility of IR780 (33.19 %) is increased by over 
2400-fold when loaded onto the GQDs-FA system, with a high photothermal conversion 
efficiency (87.9 %). The photostability and tumor-targeting ability were greatly improved 
too. Most importantly, IR780/GQDs-FA, with a particle size of about 9 nm, is capable of 
producing sufficient hyperthermia to effectively kill cervical cancer cells and completely 
eradicate tumors upon 808 nm laser irradiation.119 For future studies, it would be 
advantageous if pH-responsive features could be incorporated into this system, so that the 
therapeutic mechanism will be initiated once exposed to acidic tumor microenvironment.  
Generally, the clinical translation of PDT is often challenged due to the low yield of ROS, 
poor tissue penetration depth of the photosensitizer and short lifetime of ROS.57,120 A 
mitochondrial specific PDT, named UCNP-GQD/TRITC, has been presented with the use of 
rare-earth doped UCNPs mediated NIR-GQD.120 UCNPs are a kind of inorganic 
nanomaterials capable of emitting efficient and sharp visible or UV light when excited at 
NIR. These features of UCNPs permit high penetration depth in biological tissues with high 
detection sensitivity.121 Generation of singlet oxygen by the GQD becomes more prominent 
after UV light emission from UCNPs (see Figure 4c).120 The high concentration of singlet 
oxygen observed in mitochondria is due to intrinsic advantages of GQD as well as the highly 
efficient energy transfer from UCNPs to GQD. Furthermore, surface modification of UCNP-
GQD with mitochondrial-targeting fluorescent probe, tetramethylrhodamine-5-isothiocyanate 
(TRITC), allows the system to target mitochondria precisely and triggers breast cancer cells 
apoptosis irreversibly (with an inhibition ratio of more than 75 %).120 However, toxicity from 
long-term exposure and high quantum yield of singlet oxygen, surface-dependent therapeutic 
responses, and biological corrosion resistance (a phenomenon in which metallic ions and 
particles are released in a complex aqueous environment through electrochemical 
processes)122 of the GQD are some of the concerns raised regarding this strategy. Also, since 
GQD (with a 6 nm diameter) is attached on the surface of UCNPs via amide linkages, it is 
possible that the resultant UCNP-GQD/TRITC composites would cleave off easily when the 
system is dispersed in a solvent. Glycyrrhetinic acid (GA), a natural product from 
Glycyrrhiza glabra, is another mitochondrion targeting ligand.123 A biocompatible GA-
functionalized GO has been fabricated and used as a carrier for targeted delivery of DOX into 
mitochondria. Both in vitro and in vivo studies revealed the activation of the mitochondria-
mediated apoptosis pathway, suggesting GA-GO@DOX’s potential for liver cancer 
treatment.123  
Zhao et al. (2018)111 has presented a chitosan/dimethymaleic-modified chitosan (CS/CS-
DMMA)-functionalized GO NPs, also known as GON/CS/CS-DMMA. Chitosan (CS), a 
natural polysaccharide that commonly exists in the hard shells of marine crustaceans, has 
been actively explored to construct various CS-based nanomaterials because of its 
biocompatibility, biodegradability and structural variability.124 This hybrid nanocarrier is pH-
sensitive and has surface charge-reversible ability, which is due to self-assembly of 
deprotonated carboxyl of GO NPs and the protonated amine of CS via electrostatic 
interactions. A chemotherapeutic drug, DOX, was adsorbed onto the GO via π-π stacking 
interaction between the large π conjugated structures of GO and the aromatic structure of 
DOX. The outer CS-DMMA polyelectrolyte shell of the nanocarrier is negatively charged 
which prevented premature release of the co-loaded DOX, when circulating in the blood 
system. Upon reaching the slightly acidic microenvironment (pH 6.5) of liver cancer, the 
nanocarrier switches to positive charge, due to detachment of chitosan coating, which re-
expose the amino groups of the positively charged CS. Consequently, GON/CS/CS-DMMA 
was capable of delivering DOX effectively at a controlled release rate.111 In another study, 
reduction and functionalization of GO using dopamine formed reduced graphene 
oxide/polydopamine (RGO-PDA).109 The formed PDA stabilizes the RGO against 
agglomeration and fouling effects. It also attenuates the in vivo toxicity of RGO and allows 
covalent surface modification with desired molecules. Conjugation of BSA (as a drug carrier, 
capturing agent for 4T1 breast cancer cells) onto the RGO-PDA system further permits a 
higher loading of MRI contrast agent diethylenetriaminepentaacetic acid (DTPA)-Mn(II) 
complex and anticancer drug (MTX). This multifunctional and biocompatible theranostic 
hybrid system is electrochemically proved to allow higher sensitivity (by a factor of four) 
towards breast tumor.109  
 
Figure 4 Brief overview of graphene for nanotheranostics. (a) Illustration of hyaluronic 
acid-coated graphene oxide synthesis and its theranostic effect by targeting oncogenic 
miR-21. Reprinted with permission from ref 110. Copyright 2017 Elsevier. (b) Schematic 
illustration of the IR780 iodide on folic acid-functionalized graphene quantum dots for 
targeted PTT. Reprinted with permission from ref 119. Copyright 2017 American 
Chemical Society. (c) Overview of mitochondrial specific PTT by rare-earth 
nanoparticles mediated near-infrared graphene quantum dots. Reprinted with 
permission from ref 120. Copyright 2018 Elsevier. 
Liquid tumor 
Although the nanotheranostic strategies are focused more on the diagnosis and therapy of 
solid tumors, a considerable increase in their application to liquid tumors has been noted in 
recent years. However, while it is true that liquid tumors are classified as leukemia, 
lymphoma and myeloma, only the former two have generated interest in the scientific 
community.37 The strategy to carry out nanotheranostics in tumors are selected according to 
several variables, the most important being the disposition and accessibility of the tumor by 
the nanomaterials. Liquid tumors are more accessible than solid tumors, since they are 
present throughout the bloodstream, whereas in solid tumors, the nanostructures must cross 
tissue barriers to detect and treat.125 In this section, we will evaluate how and why the specific 
nanomaterials are selected to carry out nanotheranostic strategies in liquid tumors. 
Metal nanoparticles 
Metal NPs are presented as an interesting strategy for the detection and therapy of lymphoma 
and leukemia. Their ability to generate heat from the optical energy allows them to be 
nanoagents for PTT. However, its application for liquid tumor theranostics have not been 
fully studied and this is due to the fact that these types of circulating tumors are not located at 
a certain point and therefore may cause ablation of adjacent tissue.126 In this context, 100 nm-
sized iron oxide NPs (IONPs) functionalized with FA have been evaluated as promising 
platform for imaging followed by therapy of tumors related to the lymphatic system. Coating 
with FA does not require the use of linkers and therefore prevents the NPs from being 
oversized and enhances its accessibility to the lymph vessels. Moreover, FA provides stability 
to the NPs as it provides a negative surface charge, and this increases its retention in vessels. 
Finally, FA on the IONPs could specifically recognize the folate receptor that is 
overexpressed on the surface of cancer cells.127 However, IONPs tend to aggregate when 
placed in biological suspensions and therefore its heating ability is reduced. In order to 
exceed this limitation, IONPs have been functionalized with a protective mesoporous silica 
shell, which gives high heating and relaxivity properties when applied in vivo, while keeping 
its size below 100 nm.128 Moreover, it should be noted that unlike other metal NPs, these 
modified IONPs allow positive MRI contrast by displaying bright region and therefore allows 
effective visualization of the tumor. However, although this nanoparticle has interesting 
properties, its effectiveness for magnetic hyperthermia therapy of circulating cancer has yet 
to be demonstrated. The nanomaterial that has proved to be an excellent nanotheranostic 
agent for in vivo leukemia treatment is Cu-Au alloy nanostructures, where the higher thermal 
conductivity of the copper allows excellent heating under laser irradiation once the tumor is 
visualized by NIR imaging. This nanoplatform was proven to target and destroy cancer cells 
in mice within five minutes (see Figure 5a).129 Despite this, issues concerning renal clearance 
and lymphatic fenestration are hindering the current nanotheranostic strategies for liquid 
tumor treatment. In this context, it is essential to select nanomaterials with a size range from 
20-50 nm, as they have proven to enhance in vivo tumor penetration and inhibition.130  
Lanthanide-doped nanoparticles 
The lanthanide oxyfluoride NPs appear as an alternative to lipid and polymeric based 
delivery systems, which have low retention and non-specific cellular uptake, respectively.131 
The excellent photoluminescence property of the lanthanide and the conjugation of the 
nanoparticle with anti CD33 antibody enable it to be an interesting nanotheranostic agent for 
myeloid leukemia. These NPs are conjugated with anti CD33 that allows retention and 
internalization in CD33+ AML cells, which otherwise could not accumulate in the blood 
vessels and therefore making it effective for diagnosis and therapy. (see Figure 5b).131 They 
have shown to be successful antitumor agents both in vivo and ex vivo by acting as a specific 
delivery vehicle of PMI peptide, which antagonizes the inhibitors of the tumor suppressor 
protein p53.  
Polymeric nanoparticles 
Polymeric NPs have been applied mostly for image-guided anticancer drug delivery. In this 
context, several types of polymeric NPs have been used depending on the diagnostic strategy 
to be followed. For the treatment of non-Hodgkin lymphoma, amphiphilic polymers 
composed of hydrophobic fluorescent curcumin and hydrophilic PEG were designed as self-
assembled anti-cancer drug nanovesicles [see Figure 5c (i)].132 Limitations associated with 
the drug, such as low solubility and low bioavailability, was curtailed with PEG. The most 
attractive aspect of this nanomaterial is the ability of curcumin to act as both a strong 
fluorescent probe and an anti-cancer drug, avoiding the need of a fluorophore.133 
Furthermore, a multifunctional imaging theranostic approach based on core-shell chitosan-
HA NPs has been applied in murine model of B-cell lymphoma.134 Since they are initially 
conjugated with fluorophores and then loaded with paramagnetic tracers, the most suitable 
imaging agent can be chosen depending on the tumor type; fluorescent reflectance imaging 
for scanning of superficial structures such as sentinel lymph node and MRI for deep tissue 
visualization. Another advantage is that the HA has numerous active groups that are useful 
for specific targeting. In this context, these polymeric NPs were decorated with a specific 
mimotope (pA20-36) that exclusively recognize A20 lymphoma cells and induce cell 
apoptosis. Moreover, amphiphilic perylene diimide (PDI) derivatives were developed and 
further self-assembled into a series of PDI NPs with different sizes of 30, 60, 100, and 200 
nm. They have been proven to perform activable PAI and effective PTT [see Figure 5c 
(ii)].135  
Lipid nanoparticles 
Lipid NPs have also been applied as carriers for lymphoma theranostics, but as an alternative 
to improve cell internalization and simultaneous drug delivery. Liposomes that contain 
SPIONs and functionalized with rituximab antibody has been developed as theranostic agent 
for central nervous system lymphoma (see Figure 5d).136 Blood-brain barrier regulates the 
movement of molecules, ions and cells between the continuous non-fenestrated 
microvasculature and the central nervous system.137 The restrictive nature of the blood-brain 
barrier pose challenges for targeted drug delivery to the central nervous system, and it is 
usually associated with neurological diseases including neurodegenerative diseases.138 In this 
case, free rituximab is not able to cross the blood-brain barrier, hence it requires a drug 
delivery system to perform effective therapy. The liposome is used as a rituximab vehicle, 
with sizes of less than 200 nm. Surface modification of liposome with a non-ionic surfactant 
allows penetration into the blood-brain barrier and therefore can develop its antitumor 
function. The liposome which also contains SPIONs allows in vivo MRI with both T1 and T2 
modes. Nevertheless, the anti-lymphoma activities of the liposome have only been tested in 
vitro and therefore this strategy only remains as a promising tool for clinical translation.136  
 
Figure 5 Nanomaterials applied as theranostic agents for liquid tumor. (a) Metal 
nanoparticles. Cu–Au alloy nanostructures coated with aptamers for NIR imaging and 
photothermal therapy in in vivo leukemia cancer theranostics. Adapted with permission 
from ref 129. Copyright 2016 Royal Society of Chemistry. (b) Lanthanide-doped 
nanoparticles. Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody 
and a p53-activating peptide for acute myeloid leukemia therapy. Adapted with 
permission from ref 131. Copyright 2018 Elsevier. (c) Polymeric nanoparticles. (i) 
Curcumisome loading on nanovesicles for fluorescence imaging and drug delivery 
strategy in leukemia theranostics. Adapted with permission from ref 132. Copyright 2015 
Royal Society of Chemistry. (ii) Application of perylene diimide nanoparticle on lymph 
node mapping and cancer photoacoustic imaging and photothermal therapy. Adapted 
with permission from ref 135. Copyright 2017 American Chemical Society. (d) Lipid 
nanoparticles. Application of liposome-containing SPIONs conjugated with anti-CD20 
antibody as a theranostic agent for central nervous system lymphoma. Adapted with 
permission from ref 136. Copyright 2018 Elsevier. 
NEURODEGENERATIVE DISEASES  
Neurodegenerative diseases are a set of heterogeneous disorders that result in a progressive 
loss of certain neuronal systems and finally loss of cognitive abilities. Alzheimer's disease 
(AD), Parkinson's disease, amyotrophic lateral sclerosis and Huntington's disease are the 
prototypes of degenerative diseases.139 Among them, AD is the most common 
neurodegenerative disorder, and this is the reason that most of the nanotheranostic strategies 
applied on brain diseases are focused on this specific disorder. While it is true that the 
causative mechanism of the disease is unknown, there are several hypotheses that consider 
the deregulation of metal levels in the brain is associated with multiple pathological factors of 
the disease, such as amyloid aggregation and oxidative stress. In this context, the 
nanotheranostic platforms are classified according to the therapeutic strategy to be performed, 
which is usually the amyloid-β aggregation inhibition and metal chelation.140  
Nanomaterials for amyloid-β aggregation inhibition 
The application of nanotheranostics to AD is a clear example of how nanoplatform is 
designed according to the type of therapy to be performed. Unlike nanotheranostics for 
cancer disease, in which the therapy is usually tumor thermal ablation or specific drug 
delivery, for AD the therapy is usually based on the inhibition of the Aβ aggregation, since 
these have a direct relationship with the disease’s poor prognosis. In this context, three NIR 
dyes (DMA-SLOH, DBA-SLOH, and DPA-SLM) for in vivo imaging of Aβ species and 
inhibition of Aβ aggregation have been developed (see Figure 6a).141 The advantage of using 
fluorescence imaging is that the use of high cost and low sensitivity MRI and positron 
emission tomography (PET) imaging (in which radioactive compounds and use of 
sophisticated instruments) are completely avoided. Moreover, the use of NIR fluorescence 
reduces the interference caused by native fluorescence biological compounds, which have 
wavelength emission peak below 550 nm. Furthermore, the NIR dyes are proven to have 
excellent blood-brain barrier permeability, good biostability and renal clearance ability.141 
However, since the strategies of nanotheranostics reported for inhibiting the aggregation of β-
amyloids have shown to fail in clinical trials, a multifunctional nanocomposite has been 
developed for the specific targeting of Tau and its aggregation inhibition. Tau aggregation is 
an independent amyloid-β AD pathology that leads to mitochondrial dysfunction and 
consequently oxidative stress generation and cognitive deficit. The nanocomposite consists of 
a mesoporous silica nanoparticle that acts as a carrier of ceria and iron oxide nanocrystals, for 
antioxidant function and MRI probe, respectively (see Figure 6b).142 The Tau aggregation 
inhibition is due to the loading of the carrier with methylene blue. This nanomaterial proved 
to be an effective in vivo theranostic agent due to its retention capability in the axon and its 
synergic therapeutic effect on AD. Despite this, in order to promote clinical translation of this 
nanoplatform, the nanocomposite must fulfill the Lipinski’s rules, which determine its 
capability to cross the blood-brain barrier.143  
Nanomaterials for Cu2+ chelation 
The process of Aβ aggregation is promoted by the increase in the concentration of trace metal 
ions, such as Cu2+; therefore, determining its concentration in the brain is an essential tool for 
diagnosis of AD. In this context, fluorescence chelators, BTTA composed of a cyclen group 
and a benzothiazole aniline group (BTA) has been developed, in which BTA allows specific 
fluorescence imaging of Aβ species and the cyclen group acts as an attenuator of the metal 
induced Aβ aggregation (see Figure 6c).144 This nanotheranostic agent satisfies the restrictive 
terms of Lipinski’s rules and has demonstrated its functionality in vitro and its ability to 
penetrate the blood-brain barrier in vivo. However, it should be noted that it requires 
structural modifications for longer fluorescence emissions or even NIR emission with 
acceptable penetration depth.144 For this reason, UCNPs modified with complex 8-
hydroxyquinoline-2-carboxylic acid (HQC) have been developed. The fluorescence emission 
of the UCNPs is quenched when Cu2+ is detected, due to luminescence resonance energy 
transfer. As the Cu2+ is captured by HQC, it inhibits the aggregation of Aβ and subsequently 
eliminates the toxic Aβ intermediates (see Figure 6d).145 Although this nanomaterial was 
reported as a promising nanotheranostic agent in human brain, it is noteworthy that the in 
vivo experiment was performed on zebrafish, which has a transparent brain compared to a 
complex human brain. In order to determine the efficacy of this nanotheranostic agent for AD 
patients, further in vivo assays should be conducted. 
 
Figure 6 Nanomaterials applied as theranostic agents for neurodegenerative diseases. 
(a) NIR dyes for in vivo imaging of Aβ species and Aβ aggregation inhibition. Adapted 
with permission from ref 141. Copyright 2016 Elsevier. (b) ceria and iron oxide 
nanocrystals functionalized nanocomposite as a nanotheranostic agent for MRI and 
Tau aggregation inhibitor. Adapted with permission from ref 142. Copyright 2018 
American Chemical Society. (c) BTTA for fluorescence imaging and Cu2+ chelators 
applied in Alzheimer’s disease. Adapted with permission from ref 144. Copyright 2016 
Royal Society of Chemistry. (d) Upconversion nanoparticles for NIR Alzheimer’s 
disease detection and therapy based on Cu2+ chelation. Adapted with permission from 
ref 145. Copyright 2016 Elsevier. 
AUTOIMMUNE DISEASES  
The immune system in our body protects us from disease and infection. However, if a person 
has an autoimmune disease, the body’s defense mechanism will launch an attack against 
specific cells, body tissues and organs of the host. Autoimmune diseases can affect many 
parts of the body and significantly affect the patient’s well-being. Environmental, infectious 
and genetic factors are some possible factors initiating or exacerbating autoimmune diseases. 
There are more than 80 types of autoimmune diseases; with the classic symptom of 
inflammation. Current clinical treatment modalities are generally non-specific and focus on 
reduction of inflammation. Moreover, the use of anti-inflammatory drugs lack of desired 
specificity, has severe toxic effects and limited therapeutic benefits.146  
NPs can be used as a drug delivery system to specifically target cells and tissues. Co-delivery 
of targeting and therapeutic agents using NPs can greatly improve pharmacokinetics and 
enhance bioavailability of therapeutics. NPs used for the treatment of autoimmune diseases 
can be classified as colloidal NPs (consist of a metal core stabilized by an organic/polymeric 
coating) and organic-based NPs (either polymeric or lipid-based).147 The biodegradability, 
biocompatibility, biodistribution and clearance of NPs are very important issues to take into 
consideration when constructing an efficient NPs-based nanomedicine for autoimmune 
disease theranostics.  
Rheumatoid arthritis  
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease, characterized by 
severe cartilage, bone destruction and massive synovial joint inflammation. Currently, there 
is no cure for RA.148 The integration of targeting and therapeutic agents in RA into a single 
nanomaterial-based theranostic platform is increasingly advancing in rheumatology. This 
section will present few nanomaterials that have been discovered lately, with the potential for 
synergistic RA theranostics.  
Activated macrophages are the main “culprit” of inflammation in RA. The macrophages 
actively release cytokines which trigger onset and persistence of RA. Dextran sulfate (DS) is 
a hydrophilic polysaccharide that can specifically target the scavenger receptor (SR, one of 
the receptors overexpressed on the macrophages). MTX is achemotherapy drug that is 
commonly used for the treatment of RA. However, the utility of MTX is limited by its severe 
drug resistance, random distribution in the body which may cause serious side effects. 
Combining both the benefits of nanoscale prodrugs and modified conjugates, a biocompatible 
polymer-drug conjugate, namely dextran sulfate-graft-methotrexate conjugate (DS-g-MTX), 
has been designed for treatment of RA (see Figure 7a).149 The conjugate (about 100 nm in 
diameter) exhibited excellent SR targeting properties, with improved anti-inflammatory 
efficiency in the affected joints of collagen-induced arthritis (CIA) mice.149 Similar work has 
also been presented by Heo et al. (2017)150 using MTX-loaded DS NPs (220 nm in diameter), 
with the loading efficiency of 73 % (see Figure 7b).150 NPs permit prolonged circulation in 
the bloodstream, passive accumulation of drugs into inflamed synovial tissues (12-fold higher 
than control), with controlled drug release at desired action sites. The results further 
confirmed that polymeric NPs are potentially useful theranostic nanomedicine for RA.150  
Solid lipid NPs (SLNs) are formed by a mixture of solid lipids dispersed in inner cores. SLNs 
are widely used as matrix for drug encapsulation, mainly because SLNs possess attractive 
features such as good physical stability, enhanced biocompatibility and biodegradability, 
protection against labile drug degeneration, controlled release and facile synthesis.98,151 HA is 
another commonly used drug carriers and targeting ligands in RA treatment.148 HA targets the 
over-expressed hyaluronic receptor CD44 on the surface of activated macrophages. 
Encapsulation of glucocorticoid prednisolone (PD) can be carried out within the SLNs 
conjugated with HA and the resultant product is known as HA-SLNs/PD, with approximately 
147.8 nm in diameter. Encapsulation of PD in HA-SLNs improved colloidal stability, slowed 
down PD release (37.6 % compared to 56.22% from free drug solution during the first 30 
hours), enhanced biodistribution and therapeutic efficacy in CIA model (with a 
histopathology score of 2.0).152  
Metallic NPs have been successfully translated to RA treatment due to their size and 
magnetic properties which can serve as a multifunctional drug delivery and theranostic 
platform.148 In a study, researchers designed drug-loaded gold/iron/gold plasmonic NPs for 
simultaneous magnetic targeted chemo-photothermal treatment and dual (NIR absorbance 
and magnetic resonance) imaging of RA.153 The NPs combine the properties of both iron 
(magnetic) and gold (surface plasmon resonance), and the gold exterior shell provides an 
anchorage site for further functionalization. Arginine-glycine-aspartic acid (RGD) peptide 
was conjugated onto the Au surface to target αvβ3 integrins expressed at the inflammation 
sites. Meanwhile, MTX was loaded inside the poly(lactic-co-glycolic acid, PLGA) NPs. 
PLGA is selected due to its excellent biodegradability, biocompatibility and stability.154 This 
RGD-conjugated MTX-loaded PLGA Au/Fe/Au half-shell NPs has an average diameter of 
135 nm. Upon NIR irradiation, NIR resonance of the Au half-shells generates heat at the 
inflammation sites to accelerate the release of MTX from PLGA NPs. Besides, the Fe half-
shell layer embedded between the Au half-shell layers allows in vivo T2- MRI and NIR 
absorbance imaging [(see Figure 7d).153 The externally generated magnetic field not only 
speeds up the delivery of the NPs to the inflammation sites, but also enhances the retention of 
the NPs. The combination of NIR absorbance imaging and MRI allow higher spatial 
resolution of inflammation regions with outstanding contrast features, higher sensitivity and 
specificity. Interestingly, the MTX dosages required in this case is only 0.05% as compared 
to free MTX therapy for the treatment of RA.153 The in vivo behavior (such as biodistribution 
and vascular penetration) of the as-synthesized NPs requires in-depth studies before wide 
clinical application.  
A combined strategy PSDT (PDT followed by sonodynamic therapy), using PLGA phase-
transition NPs co-loaded with oxygen and indocyanine green (ICG), termed OI-NPs, has been 
proposed for theranostic of RA by Tang et al. (2017).154 PSDT may reduce the sensitizer 
dosage and ultrasound/light energy that can alleviate side effects, while improving the 
curative effect dramatically. ICG can strongly absorb NIR once activated by light and 
ultrasound, suitable for therapy or imaging. The stability of the ICG is improved when co-
loaded with oxygen onto PLGA phase-transition NPs. The synergistic oxygen and ICG are 
found to act as a sensitizer and oxygen carrier for PSDT. The prepared NPs have advantages 
in terms of biosafety and stability, at the same time showing cytotoxic effects on 
synoviocytes (a specialized cell type located inside the joints, responsible in producing 
cytokines and proteases, which cause cartilage destruction).154 Nonetheless, the authors did 
not report on the performance of the as-synthesized NPs in in vivo model and its therapeutic 
effect in hypoxic environment.  
Titanium dioxide (TiO2) has shown potential in PDT for some diseases, mainly because of its 
excellent biocompatibility, easy availability and ROS generation properties upon excitation. 
Tetra sulfonatophenyl porphyrin (TSPP) is a porphyrin derivative that can generate ROS for 
PDT, but its application is often hampered by neurotoxicity, phototoxicity and non-specific 
accumulation in body tissues. Interestingly, the photo-activated TSPP-TiO2 nanocomposites 
were found to be able to ameliorate RA by PDT in CIA models, when coupled with allogenic 
bone marrow stem cells (BMSC).155 Meanwhile, Cu is an essential element in the human 
body, useful in promoting osteogenesis and chondrogenesis. Cu-based nanomaterials were 
reported as excellent PTT agents and photosensitizers for PDT. An approach using Cu-based 
nanomaterials in RA treatment has been proposed with good biocompatibility and facile 
synthesis (see Figure 7c).156 Upon NIR irradiation at 808 nm, the as-synthesized L-cysteine 
(Cys) assisted CuS NPs (named Cu7.2S4 NPs) not only showed better bone preservation, but 
also displayed outstanding antibacterial ability during intra-articular injection. Hence, the 
Cu7.2S4 NPs could serve as a synergistic PDT and PTT modality for RA.
156  
Drug delivery systems can be manipulated in a way that the nanomaterials only release the 
drug from the conjugate in response to certain conditions. This is important in avoiding 
systemic distribution of drugs in the body that necessitates the use of sustained high-dose 
therapy and may give rise to adverse effects. As such, Li et al. (2017) presented pH-sensitive 
polymeric micelles for targeted drug delivery to inflamed joints.157 The polymeric micelles 
(with particle size of 45.76 nm) are stable in the bloodstream, until it reaches the 
inflammation sites. An imbalance between increased metabolism and insufficient oxygen 
supply contributes to low pH in the inflamed synovial fluid (as low as pH 6.0, in some cases 
even lower than 5.0).158 Recognition of acidosis of synovial fluid triggers hydrolysis of 
hydrazone bonds, subsequently releasing the drug, PD in affected joint areas. Same process 
has also been reported for targeted drug delivery to the acidic microenvironment of solid 
tumors. The results demonstrated improved therapeutics efficacy, with the therapeutic 
benefits from each injection lasting for 48-72 hours in preclinical models,159 fulfilling the 
needs of sustained prodrug activation kinetics for RA treatment. The as-prepared polymeric 
micelles inevitably display minimal toxicity, which could be due to micelle uptake by 
phagocytic cells in liver and spleen that initiates inflammatory responses.157 Key mechanistic 
details that induce potential toxicity and inflammatory effects, long-term nanomaterial fates 
in clearance organs as well as macrophage-nanomaterial interactions are generally 
unexplored.160 Future research can be anticipated on fabrication of micelles with bone 
regeneration capabilities in eroded joints.  
Generally, the RA severity often fluctuates over time. Usually, the treatment offered, doses of 
drug applied and its release rates are irrespective of disease stage, resulting in non-optimal 
therapeutic efficacy with potential side effects. Herein, a drug-loaded hydrogel that responds 
to RA flare-ups in real time has been innovatively introduced.159 A hydrogel is a three-
dimensional polymer network of hydrophilic monomers that can absorb and retain a large 
amount of water, without affecting its shape. Since it can mimic a native tissue’s architecture 
and functions, hydrogel often has been used as drug-delivery carriers.161 In this case, a 
hydrogel is formed from the self-assembly of triglycerol monostearate (TG-18), encapsulated 
with drug triamcinolone acetonide (TA).159 Synovial fluid from RA joints has higher 
expression of matrix metalloproteinases (MMPs) and other tissue-degrading enzymes than 
synovial fluid from healthy joints.159 Therefore, upon exposure to synovial fluids from 
patients with RA, MMPs cleave the ester bond in TG-18, disassemble the hydrogel and 
release the encapsulated TA on-demand, which exclusively corresponds to the concentration 
of MMPs expressed in the synovial fluids. The severity of the RA is reflected by the co-
loaded fluorescent dye 1,1-dioctadecyl-3,3,3,3-tetramethylindotricarbocyanine iodide 
(DiR).159 Metalloproteinases-3 (MMPs-3) gene is one of the biomarkers of RA and often 
correlated with systemic inflammation. Although the precise role of MMPs-3 in RA 
progression requires further elucidation, TA is believed to be able to alter genes expression of 
MMPs-3.162 However, the system still requires extensive in vivo biocompatibility evaluation, 
sustained TA drug release and encapsulation studies especially in large animal models. It is 




Figure 7 Brief overview of the structure of the nanomaterials used for rheumatoid 
arthritis theranostics. (a) MTX prodrug, TEM microimages of DS-g-MTX and its ex 
vivo FITC image of affected joints. Adapted with permission from ref 149. Copyright 
2017 Ivyspring International Publisher. (b) DS-NPs as a nanocarrier for targeted RA 
theranostic. Adapted with permission from ref 150. Copyright 2017 Elsevier. (c) 
Application of Cu7.2S4 NPs in RA theranostic when combined with PTT and PDT. The 
respective TEM image, SAED and interplanar crystal spacing of Cu7.2S4 NPs. Adapted 
with permission from ref 156. Copyright 2018 John Wiley and Sons. (d) MTX-Au/Fe/Au 
plasmonic NPs for magnetic targeted chemo-photothermal treatment of RA. Adapted 
with permission from ref 153. Copyright 2015 Elsevier. 
CARDIOVASCULAR DISEASES  
Cardiovascular diseases (CVDs) are the leading cause of non-communicable illness 
worldwide. Current surgical intervention and therapy for CVDs are not completely effective 
and face many medical challenges. For instance, current recommended therapeutic regimes 
barely lead to full recovery and often involve poor efficacy, drug instability and resistance, as 
well as adverse effects and high costs.163 Advances in nanomedicine offers theranostic 
approaches for CVDs.161 It is observed that most of the scientific researches are focused on 
the study of non-invasive biological imaging applications (particularly MRI and near-infrared 
fluorescence (NIRF)) for early detection of atherosclerotic plaque. Additional therapeutic 
strategies for CVDs are highly imperative in actualizing CVDs theranostic applications. 
Atherosclerosis  
Atherosclerosis, a systemic disease affecting arteries, is the major pathological cause of 
CVDs. Atherosclerosis is characterized by the formation of atherosclerotic plaques, which are 
developed through the accumulation of cholesterol and formation of foam cells in the arterial 
wall.164 Atherosclerotic plaques tend to induce hardening of the artery and thus obstruct blood 
circulation.165  
Report for non-invasive fluorescence imaging of atherosclerosis in live atherosclerotic mice 
has been published in 2016, with the use of Simian virus 40 virus-like particles (SV40 VLPs) 
as a platform to load imaging probes, targeting elements and therapeutic compounds (see 
Figure 8a).166 Controllable in vitro self-assembly and the capacity as the cargo for foreign 
peptides or proteins, makes SV40 VLPs stand out as a nanomaterial in various 
nanotheranostic applications.167 Encapsulation of NIR QDs (QD 800) inside SV40 VLPs 
improved QDs photostability, brightness and detection sensitivity during fluorescence 
imaging of atherosclerotic plaques in mice.166 In fact, different atherosclerosis biomarkers or 
targeting peptides are present at various developmental stages of atherosclerosis.168 Vascular 
cell adhesion molecule-1 (VCAM-1), macrophages and fibrin have been identified and used 
to target atherosclerosis at early, development and late stage, respectively. The 
multifunctional QDs, with a diameter of 26 nm, permits its accumulation inside the 
atherosclerotic plaque tissues mediated by EPR effect, in response to the inflammatory 
process in the vascular. Enhanced targeted delivery of anticoagulant drug Hirulog (about 6.5-
fold increase) and higher anti-thrombin activity (1.8 µg/mg of tissue) at atherosclerotic 
plaques has been reported when QDs are functionalized with VCAM-1 targeting peptide.166 
However, the group did not provide strong justification on the atherosclerosis efficacy of 
these NPs, such as reduced areas of plaques, counts of infiltrated immune cells or the 
expression of inflammatory markers.169 Future studies should be focused on more detailed 
biocompatibility evaluation of the SV40 VLPs, including blood-half life, immunogenicity 
and comparisons with other protein cages to justify its potential as theranostic tools for 
atherosclerosis.  
H2O2 is a highly promising theranostic biomarker in various pathological disorders, however, 
its fluorescence imaging modalities are hindered by its short tissue penetration depth. ICG is a 
widely used photoacoustic contrast agent with a high signal to noise ratio and maximum 
emission at around 800 nm. Yet, its application is often challenged by instability, rapid blood 
clearance and non-targeting ability.170 Jung et al. (2018) loaded ICG onto boronated 
maltodextrin (BM) NPs to form spherical ICG-BM NPs with a diameter of 500 nm.170 
Maltodextrin, one of the polysaccharides obtained from partial hydrolysis of starch, is water 
soluble, biocompatible, biodegradable, versatile and easy to modify. Hence, maltodextrin is 
suitable to be used as a diluent, coating material and carrier of diagnostic or therapeutic 
agents in drug delivery system. Substitution of hydroxyl groups of maltodextrin with boronic 
ester forms BM, rendering maltodextrin with H2O2-responsive properties. ICG-BM NPs react 
with H2O2 to generate echogenic carbon dioxide (CO2) bubbles which significantly enhanced 
fluorescence (almost 2-fold higher); ultrasound (signal detectable even with low-frequency 
ultrasound transducer); and photoacoustic signals in H2O2-triggered manner. Moreover, ICG-
BM NPs could exert therapeutic effects by scavenging the overexpressed H2O2 and 
simultaneously release therapeutic 4-hydroxybenzyl alcohol (HBA). HBA displays anti-
inflammatory, antioxidant and antiplatelet functions by suppressing the expression of pro-
inflammatory tumor necrosis factor-alpha (TNF-α) and soluble CD 40 ligand in activated 
platelets,171 thus relieving inflammation and accelerating angiogenesis.170 Future work can be 
anticipated on reducing the size of ICG-BM, since NPs with sizes over 100 nm are easily 
recognized by macrophages and accumulate in lymph nodes, liver, spleen as well as lungs.59  
High density lipoproteins (HDL) are responsible for reverse cholesterol transport (RCT), a 
process to efflux excess cholesterol in the periphery back to the liver. RCT is important in 
protecting against CVDs. A magnetic nanostructure (MNs) functionalized with phospholipids 
and apolipoprotein A1 (apoA1), named HDL-MNs, has been developed to mimic the natural 
HDL particles present in the body (see Figure 8b).172 The MNs are biocompatible and 
composed of Fe3O4 NPs, suitable to be used as contrast agents for MRI. The use of HDL-
MNs for CVDs is a non-invasive imaging and therapeutic approach. Apart from being 
capable of precise targeting of macrophages, HDL-MNs are able to perform RCT by inducing 
cholesterol efflux (about 4.8 %, in natural HDL is about 4.7 %) from cholesterol-rich 
macrophages. The HDL-MNs have also shown 5 times higher MR contrast enhancement than 
commercial FDA approved T2 MRI contrast agent (Ferumoxytol). The HDL-MNs are found 
not inducing cytotoxicity in in vitro setting, in macrophages of up to 350 µM HDL-MNs.172 
The hydrodynamic diameter of the nanostructure, however, is approximately 80-100 nm, 
which is too big for EPR-based extravasation and may impact its circulation time in blood 
and accumulation at atherosclerotic plaques. It is of interest to further investigate the 
targeting ability of this nanostructure in in vivo setting. In addition, the use of iron-based NPs 
could potentially generate harmful radicals (Fenton reaction). This may limit their use in 
humans for diagnosis and treatment, especially under oxidative stress-related conditions.  
Recently, researchers have turned their attention to activation of transient receptor potential 
vanilloid subfamily 1 (TRPV1) signaling pathway as one of the alternatives for attenuating 
atherosclerosis (see Figure 8c).164 Activation of TRPV1 cation channels may reduce lipid 
storage and formation of atherosclerotic lesions. Yet, clinical use for the normally used 
TRPV1 cation channels activator, capsaicin, is limited by its chronic toxicity and infusibility. 
Unlike the optical absorption in gold nanostructures, which is due to the surface plasmon 
resonance, NIR absorption of CuS NPs derives from the d-d transition of Cu2+ ions. In other 
words, CuS NPs absorption would less likely be influenced by the solvent or the surrounding 
factors, which is perfect for in vivo setting. CuS NPs also possess almost analogous high heat 
conversion efficiencies (as high as 80 %) compared to gold nanostructures, making them 
remain stable under prolonged optical excitation.173 Coupling of CuS NPs to antibodies 
targeting TRPV1 acts as a photothermal switch for TRPV1 signaling in vascular smooth 
muscles. Upon irradiation of CuS NPs by continuous wave laser at 980 nm, 5 W/cm2 for 350 
s, the NPs (with particle size of 13 nm) generate local heat and strong photoacoustic signal 
which subsequently opens TRPV1 channels and causes calcium ions (Ca2+) influx. The 
increase in intracellular Ca2+ induces autophagy, reduces lipid accumulation and foam cell 
formation. The cholesterol efflux was enhanced with no obvious long-term toxicity in vivo. 
With photoacoustic imaging, high resolution visualization with high temporal and spatial 
precision of blood vessels in the deeper cardiac regions (such as aortic arch, carotid artery 
and femoral artery) were achieved.164  
 
Figure 8 Brief overview of the structure of the nanomaterials used for atherosclerosis 
theranostics. (a) Multifunctional virus-like particles of Simian Virus 40 NPs (SV40 
VLPs) with the TEM image. Adapted with permission from ref 166. Copyright 2016 
American Chemical Society. (b) High-density lipoprotein-like magnetic nanostructures 
(HDL-MNs) with their TEM images when synthesized using different approaches. 
Adapted with permission from ref 172. Copyright 2017 American Chemical Society. (c) 
Copper sulfide (CuS) NPs as a photothermal switch for TRPV1 signaling to attenuate 
atherosclerosis, with the TEM image. Adapted with permission from ref 164. Copyright 
2018 Springer Nature.  
Thrombosis 
The vulnerable plaques located in the arterial wall are prone to rupture due to soft and weak 
fibrous cap. The rupture exposes collagen and various components to the blood, leading to 
the formation of blood clots (thrombi (plural); thrombus (singular)) in the lumen. This 
condition is known as arterial thrombosis.164 Thrombosis rarely show any symptoms until late 
stage and sudden death.174 Generally, a thrombus is made up of blood factors, mainly 
activated platelets and water-insoluble fibrin. P-selectin is an adhesion molecule mainly 
involved in the pathophysiology of thrombosis and other CVDs.174 Li et al. (2018) 
innovatively functionalized fucoidan, a marine polysaccharide that specifically targets P-
selectin in thrombus, on polysaccharide-coated microbubbles (MBs).174 Ultrasound imaging 
is one of the commonly used medical diagnostic imaging modalities owing to their 
portability, non-invasiveness with excellent safety profile, high spatial resolution, lack of 
ionizing radiation, reasonable cost and real-time imaging properties.59 The as-synthesized 
fucoidan functionalized microbubbles (fucoidan-MBs) exhibit high echogenicity and stability 
in suspension at 4°C (up to 2 months),174 hence suitable to be used as a sensitive molecular 
ultrasound contrast agent by creating strong acoustic reflections that may identify thrombus. 
However, possible treatments for thrombosis after imaging are not discussed by the authors 
of this study. Future studies could, therefore, focus on theranostic capabilities, safety and 
efficacy of fucoidan-MBs, as well as the possibility of incorporation of antithrombotic drugs 
into the system. 
A thrombus is also usually associated with an elevated level of H2O2. H2O2 is an important 
signaling messenger regulating the activity of signaling proteins, enzymes and ion channels. 
Upregulation of H2O2 may bring harmful oxidative damage, leading to apoptosis and tissue 
damage.161 Inspired by these phenomena, fibrin-targeted imaging and anti-thrombotic 
nanomedicine (FTIAN) has been constructed for thrombosis theranostic (see Figure 9a).165 
With a diameter of 160 nm, FTIAN has been prepared from self-assembly of IR820 NIR 
fluorescent dye-conjugated boronate antioxidant polymers (fBAP) and lipopeptides (lipid-
PEG-CREKA) composed of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), PEG, 
and a pentapeptide, CREKA (Cys-Arg-Glu-Lys-Ala). High level of H2O2 in thrombus 
oxidizes boronate in FTIAN and stimulates subsequent release of HBA from fBAP,165 
initiating antioxidant and anti-inflammation activities.171 On the other hand, high affinity of 
CREKA in the lipopeptide towards fibrin facilitates the specific targeting of fibrin on the 
obstructive thrombus using FTIAN. With the use of IR820 as an NIR fluorophore and 
photoabsorber, the fluorescence/photoacoustic imaging of thrombi has also significantly 
enhanced by 5-fold. Most importantly, the intrinsic anti-thrombotic activity of FTIAN has 
suppressed thrombus formation (required a dose of 24 µg/kg of tirofiban only as compared to 
a clinically used dose of 80 µg/kg).165  
Another thrombus-specific theranostic (T-FBM) NPs have been developed with a mean 
diameter of 260 nm (see Figure 9b).171 T-FBM NPs is composed of lipopeptide, 
GPRPPC−PEG−DSPE (distearoylphosphatidylethanolamine). The pentapeptide, GPRPPC, is 
used to target the thrombus since it has high affinity to fibrin as well. PEG (3.4 k) serves as a 
surface corona which may prevent non-specific interaction of T-FBM NPs with plasma 
proteins. The ultrasound/photoacoustic contrast of T-FBM NPs has been significantly 
enhanced (by 5-fold) when triggered with H2O2. This is because H2O2 generate CO2 bubbles 
to amplify the photoacoustic signal. These NPs are also suitable to be used as an anti-
thrombotic nanomedicine, since the NPs can release anti-oxidant and anti-inflammatory HBA 
under oxidative stress-related conditions. Based on the findings, there is an obvious 
suppression of the thrombus formation in the studied mouse models. However, for most of 
the works described in this section, the researchers did not report the dose, pharmacokinetics, 
side effects and toxicology of the NPs used. In fact, the biocompatibility and biodegradability 
of the NPs are equally important in future clinical applications. Also, unlike non-motile solid 
tumor, thrombi ultrasound imaging analysis is often challenged by poor contrast resulting 
from the interference of motion artifact caused by respiratory and cardiac activities.174  
 
Figure 9 Brief overview of the nanomaterials used for thrombosis theranostics, with 
their TEM images. (a) Fibrin-targeted and H2O2-responsive NPs as a theranostics for 
thrombosed vessels. Adapted with permission from ref 165. Copyright 2017 American 
Chemical Society. (b) T-FBM NPs as a H2O2-activatable photoacoustic signal amplifier 
and a thrombus-specific nanotheranostic agent. Adapted with permission from ref 171. 
Copyright 2018 American Chemical Society.  
BACTERIAL INFECTION  
Bacterial infection is one of the world’s leading causes of premature deaths and mortalities. 
Current methodologies for diagnosis and therapy of bacterial infection are often hindered by 
a difficult bacteria isolation and early detection, low numbers of bacteria in the clinical 
specimen, false negatives and contamination of the specimen.1 Poor sensitivity and late 
diagnosis often delay the therapy and thus increase the cost and discomfort to the patients. 
The development of drug resistance in the bacterial pathogen and the overuse of antibiotic are 
also concerns in bacterial infection management. This section will discuss different 
nanomaterials with their potential in bacteria nanotheranostics and provides a critical review 
on their advantages and limitations. 
The work on both in vitro and in vivo multi-modal mapping and targeted PTT against 
bacterial infection of gastrointestinal tract was introduced in 2015, with the use of tungsten-
based theranostic agents.175 Since then, different nanoprobes capable of selectively imaging 
bacteria with high anti-microbial properties have been proposed. Selenium (Se) is a semi-
metallic element with low electronegativity and large atomic radius compared with sulfur, 
endowing Se-containing compounds with high reactivity and sensitivity.176 Moreover, the 
stimulus-responsive property of Se gives the materials a big potential in construction of smart 
and sensitive theranostic systems responding to biomolecules.176 Ruthenium (Ru) is a rare 
metal in the earth’s crust with diverse biomedical and antimicrobial applications, especially 
in its complex form.177 For instance, Ru complexes have been found to display synergistic 
antimicrobial activity with antibacterial peptide UBI29-41 (PEP)-modified Se particles (see 
Figure 10d).178 This multifunctional theranostic nanoplatform, or known as Se@PEP-Ru 
NPs, displayed good biocompatibility, excellent selectivity and potent antimicrobial activity. 
The NPs strongly interact with both gram-positive and gram-negative bacteria cell 
membranes, followed by severely damaging the structures of the bacterial cell and 
cytoplasmic membranes. The wound sizes of the mice treated with Se@PEP-Ru NPs were 
found to decrease by about 40% at the fourth day after surgery, showing a significant 
therapeutic effect. Besides, since Se@PEP-Ru NPs are sensitive to sites of bacterial infection, 
it was found to be able to identify and distinguish bacterial infection from inflammation and 
tumor-induced tissue infection with high specificity.178 Evident fluorescence can be observed 
(after 4-48 hours of injection) at the site of the bacterial infection but the fluorescence was 
almost negligible (2-3 times weaker) at the site of inflammation. Future studies can be 
focused on engineering the as-synthesized Se@PEP-Ru NPs (with a size of about 78 nm) into 
a smaller size as the size and surface area of NPs could affect the antibacterial activity.179 
Smaller NPs (less than 10 nm) are generally more effective since it allows favorable surface 
area of NPs for interaction with the bacterial cell membrane and disruption of bacterial 
permeability and respiration.180  
Metabolic biomolecular labelling is an emerging technology to modify the surface of cells 
and pathogen with chemical functional groups, which in turn allows conjugation of 
fluorescent dyes (for imaging purpose) or drugs (for therapeutic effect) onto cell 
membrane.181 Metal-organic frameworks (MOFs) can be engineered as drug nanocarriers, 
thanks to their versatile chemical properties, good biocompatibility, sensitive to low pH 
tumor environment and fast body clearance after drug delivery. A bacteria theranostic 
strategy through coupling of MOFs with metabolic labelling technique has been reported 
recently (see Figure 10a).181 Mao et al. (2018)181 innovatively used MIL-100 (Fe) 
nanoparticles (with an average diameter of 120 nm) as the nanocarriers for metabolic 
labelling molecule and 3-azido-D-alanine (D-AzAla), to target bacterial cells. The NPs are 
stabilized by polymer pluronic F-127. The high H2O2 inflammatory environment stimulates 
degradation and rapid release of D-AzAla from MIL-100 (Fe) at the inflammation sites. Upon 
internalization of D-AzAla by the bacteria, unnatural azide groups will be expressed on the 
bacterial cell walls. Ultrasmall photosensitizer NPs with around 10 nm, named 
dibenzocyclooctyne (DBCO)-modified 2-(1-(5-(4-(1,2,2-tris(4-
methoxyphenyl)vinyl)phenyl)thiophen-2-yl)ethylidene)malononitrile NPs (US-TPETM NPs), 
with aggregation-induced emission characteristics are subsequently administered. DBCO 
groups on the surface of NPs will bind and react with the bacteria through in vivo click 
chemistry. The bacterial cell walls will be lightened up to produce fluorescence signals for 
imaging, facilitating subsequent image-guided antibacterial therapy and PDT.181 This 
breakthrough in in vivo incorporation of unnatural functional group into bacteria for 
metabolic labelling and antibacterial therapy could soon enable the discovery of more 
effective bacterial theranostic approaches.  
Luminescent porous silicon (LuPSi) has tunable porosity and surface chemistry, good 
biocompatibility and degradability, making them suitable as optical biosensors for 
bioimaging and drug delivery. LuPSi can be loaded with antibiotics ciprofloxacin (CIP) to 
form CIP-LuPSi for theranostic application.182 For wound care application, a smart bandage 
composed of polyurethane (PU) membrane and chitosan film, has been presented by Chen et 
al. (2017) for monitoring and inhibition of wound infection.182 High level of ROS and 
elevated pH (above 7.4, normal skin pH= 5.5- 6) are two main biomarkers in chronic or 
infected wounds.182 The luminescent property of LuPSi is correlated with its surface 
chemistry. The blue luminescence of CIP was quenched by red LuPSi due to the fluorescence 
resonance energy transfer (FRET) effect. When the smart bandage is applied onto the 
infected wound that usually associated with an elevated level of ROS and alkaline ions (such 
as PO4
3- or OH-), the surface of LuPSi was oxidized into an insulating oxide layer that 
blocked the energy transfer between LuPSi and CIP. As a result, the fluorescence of CIP 
recovered (from red to blue) and can be observed by naked eyes and a cell phone camera. 
Therefore, by detecting the ratiometric fluorescence intensity, the kinetic process of surface 
oxidation of CIP-LuPSi can be precisely measured. The oxidation of LuPSi also 
simultaneously trigger the release of CIP to inhibit bacterial activity. In the same year, Zhao 
et al. (2017) developed silica NPs coated with vancomycin-modified polyelectrolyte-cypate 
complexes (SiO2-Cy-Van), with a size of about 72.7 nm, as a bacteria-activable theranostic 
nanoprobe (see Figure 10c).183 The polyelectrolyte acts as an adsorbate or dissociation energy 
barrier on silica NPs, conferring the NPs with bacteria-responsive feature, as well as 
enhanced biocompatibility and relatively prolonged blood circulation. The cell wall of 
methicillin-resistant Staphylococcus aureus (MRSA) bacteria is capable of forming hydrogen 
bonding with vancomycin (Van) on the nanoprobes. The interaction between Van and MRSA 
detaches the layer-by-layer assembled polyelectrolytes from silica NPs, changing the state of 
cypate (Cy), a dye with NIR fluorescence emission at around 825 nm, from OFF 
(aggregation) to ON (disaggregation). This leads to rapid MRSA-activated NIR imaging (4 
hours post-injection, high sensitivity up to 105 colony-forming units) and effective PTT upon 
808 nm laser irradiation.183 However, the possibility of autofluorescence and influences of 
bacterial environment on the sensitivity and selectivity of the nanoprobes are not clearly 
demonstrated. On the other hand, the idea of bacteria-responsive intelligent wound dressing 
proposed by Zhou et al. (2018)184 has also offered a different perspective in the fabrication of 
nanomaterials to combat bacterial infection. The group constructed a biocompatible UV-
photocrosslinkable methacrylated gelatin (GelMA) encapsulating both antimicrobials and 
self-quenching dye carboxyfluorescein vesicles. The working principle is that upon bacterial 
infection, toxins or enzymatic factors secreted from bacteria could break down the lipid 
vesicles and release the payloads. This eventually leads to bacterial inhibition in addition to a 
visual color change (due to the fluorescence recovery of carboxyfluorescein). Supported by 
both in vitro and in vivo studies, the release of antimicrobials occurs only when pathogenic 
bacteria (specifically MRSA and Pseudomonas aeruginosa) exist.184  
Gold nanomaterials are antibiotic agents owing to their tunable size, facile functionalization 
and minimal toxicity. It is interesting that recently, gold nanoclusters (AuNCs) have been 
demonstrated to exhibit anti-bacterial activity,185 especially by manipulating their surface 
ligand chemistry.186 Quaternary ammonium (QA) capped AuNCs (QA-AuNCs), with the size 
about 2 nm, can selectively target MRSA and Van-resistant Enterococci (VRE), in vivo.185 
Since QA-AuNCs can disrupt the bacterial cell membrane (in terms of integrity, permeability 
and inner potential), catalyze the generation of ROS and disturb the intracellular metabolic 
pathway of the bacteria, QA-AuNCs displayed excellent therapeutic effects. The intensely 
fluorescent QA-AuNCs interact with live/dead bacteria differently, suggesting their potential 
for image-guided bacteria discrimination and counting. Besides, QA-AuNCs are stable for 
long-term storage, even at room temperature.185 On the other hand, it should be noted that it 
is difficult to compare the anti-bacterial performances of different nanomaterials, since the 
composite design and concentration of each multifunctional nanomaterial used can be very 
different, unless more comparable studies are conducted under standard experiment 
conditions.  
Gold nanorods (AuNRs) are an excellent contrast agent for PA imaging and have 
characteristic strong NIR absorption. Kim et al. (2018) have developed a gold/silver hybrid 
NPs, named as Au/AgNRs, as theranostic antibacterial/photoacoustic agent (see Figure 
10b).187 Au/AgNRs (with a diameter of 104.9 nm) are formed by coating AuNRs with silver 
(Ag) to decrease the photoacoustic signal.187 Oxidative etching of the Ag shell induced by the 
addition of ferricyanide solution (1 mM) could recover the photoacoustic contrast as the Ag is 
released. The release of Ag also effectively triggers and monitors the release of Ag+ ions (a 
well-known antibacterial agent) from its reservoir AgNPs. Ag+ ions exhibit strong 
bactericidal efficacy towards both MRSA (32 µM Ag+) and Escherichia coli (8 µM Ag+). 
The photoacoustic signal increased by 730 % pre- and post-etching, and the bacterial counts 
in infected tissues were reduced by 1000-fold (log CFU/g= 4.15 vs 7.75) in the treated 
group.187 This is the only report that quantitates Ag release in vivo and correlates the released 
dose to antibacterial outcomes.  
Hydrogels are the three-dimensional water-swollen polymer networks composed of 
hydrophilic polymers. It can be used as a scaffold for local bacterial drug delivery since it can 
achieve long retention at the focal area with low unwanted diffusion.188 A NIR light-
triggerable and thermo-sensitive hydrogel that can combat bacterial infection and promote 
wound healing have been introduced recently.188 This injectable hydrogel is composed of 
ciprofloxacin (Cip)-loaded polydopamine NPs (PDA NPs) and glycol chitosan (GC). The 
aromatic rings on the surface of PDA NPs enable the adsorption of drugs via - stacking 
and hydrogen bonding; while the quinone groups on the surface of PDA NPs allow facile 
conjugation with the chemicals containing thiol or amine groups. GC is rich in amine, 
therefore, has been used to crosslink with PDA NPs. With a uniform size of about 30 nm, 
PDA NPs also possess excellent photothermal effect (the ability to convert NIR light into 
heat), biocompatible and biodegradable. The positive charge of GC and the adsorbability of 
PDA NPs are able to trap bacteria on the surface of the hydrogel with minimal leakage under 
physiological conditions. Once irradiated with NIR light, Cip antibiotic will be released. 
Meanwhile, PDA NPs in the hydrogel will be activated and subsequently generate local heat 
to kill the bacteria, with a bactericidal efficacy up to 98.9 %.188  
Despite its efficacy, inorganic NPs as antibacterial agents are constrained by their non-
specific biological toxicity or potential long-term in vivo retention. Applications of metal-free 
antibacterial agents such as polymers are still facing limitations, including poor 
biocompatibility, complicated synthetic steps, limited structural tunability and/or the need for 
suitable carriers to ensure the spatial stabilization at the injection site. Generally, it is difficult 
to compare different nanomaterials from the aspects of their photothermal conversion 
efficiency or bactericidal performances. 
 
Figure 10 Brief overview of the nanomaterials used for bacterial infections theranostics, 
with their TEM images. (a) H2O2-responsive MOFs assisted in vivo metabolic labelling 
of bacteria and precise antibacterial therapy. Adapted with permission from ref 181. 
Copyright 2018 John Wiley and Sons. (b) Formation of Au/AgNRs hybrid NPs by Ag 
coating on AuNRs. The addition of ferricyanide solution results in oxidative etching of 
the Ag shell. Adapted with permission from ref 187. Copyright 2018 American Chemical 
Society. (c) SiO2-Cy-Van as a theranostic nanoprobe against MRSA infections. Adapted 
with permission from ref 183. Copyright 2017 American Chemical Society. (d) 
Fabrication of Se@PEP-Ru NPs for identification of bacterial infection with 
simultaneous targeted antibacterial activity. Adapted with permission from ref 178. 
Copyright 2017 Elsevier.  
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 Escherichia coli (8 
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fold (log CFU/g= 
4.15 vs 7.75) after 
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 Inorganic NPs CIP-LuPSi  17.3 Bacterial 
inhibition via 
drug release 



















dissociation of the 
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imaging (4 hours 
post-injection, 
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CLINICAL TRANSLATION OF THERANOSTIC NANOMATERIALS 
While we focus here on nanotheranostics of different diseases (see Table 2), theranostic 
nanomaterials in human clinical trials are still in its infancy when compared to its NPs 
predecessor, which focuses only on either imaging, diagnostics or therapy. There are 
numerous review articles on NPs for single function that are in clinical trials.190–194 An all-in 
treatment (comprising of imaging, diagnosis and therapy) is lucrative, however, years of 
clinical trials are required in order to gain patients’ confidence.  
Based on our extensive search, only one nanoparticle qualifies as a theranostic agent: 
gadolinium nanoparticles (GdNPs), under the name of (AGuIX) where imaging, targeting and 
therapy were incorporated into a single system.88 GdNPs in the AGuIX function as a 
radiosensitizer. GdNPs improve tumor-targeting and diagnosis of HCC using external beam 
radiotherapy.195 Conjugation of cisplatin and polysiloxane on the GdNPs allows therapy and 
passive tumor-targeting, respectively. Besides, functionalization of AGuIX NPs with a 
chelator of radiometal (64Cu or 68Ga), NIR heptamethine cyanine dye and a bioconjugatable 
handle form a trifunctional (PET, MRI and optical) imaging probe with fast tumor 
accumulation and renal clearance.196 AGuIX demonstrated an enhanced MRI contrast than 
other FDA-approved Gd chelates, and is currently under Phase Ib clinical trials and estimated 
to be completed in April 2021.197  
Another close relative is the NBTXR3, a hafnium oxide radio-enhancer, which have been 
used in various types of cancer patients and is currently in Phase II-III clinical trials. Besides 
these, there are various NPs in clinical trials that have successfully incorporated dual-
functions: either as imaging and targeting or imaging and therapeutic agent. Magnetic NPs 
have been used for anemic patients as therapy and recently developed as an MRI-contrast 
agent. Some commercially known brands (such as Ferumoxtran and Ferumoxytol) are ultra-
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small SPIONs NPs coated with either dextran or synthetic carbohydrate shell. SPIONs NPs 
were initially tested clinically on various types of cancer (such as head, neck, prostate and 
cervical cancer) by differentiating cancerous and non-cancerous lymph nodes with the aid of 
an MRI. 104,198 Recently, SPIONs NPs have been used in diagnosis of multiple sclerosis, 
myocardial infarction diseases (see Table 2). Some Phase I clinical trials have been 
completed and a few studies have even advanced to Phase IV.199,200  
Similarly, AuNPs have been translated into clinical trials since year 2008 and have been used 
for thermal ablation of tumors.191,192 However, to the best of our knowledge, AuNPs has 
advanced to only Phase I clinical trials due to the limitation in penetration depth of laser light 
during PTT and their application in vivo.17,201,202 The use of a fibre optic NIR laser for deeper 
laser penetration into tumors or a synergistic PTT and other therapies (or surgery) are some 
of the possible alternatives to the use of nanomaterials for PTT.17  
Another addition to clinical trials is the Cornell or C dots which are inorganic protein-coated-
fluorescent-silica NPs with potential in theranostics of melanoma.203 C dots allow real-time 
pre-operative and intraoperative sentinel lymph node (SLN) tissue localization and retention 
using a hand-held fluorescent camera.79 Although complete lymph node dissection for 
patients who had SLN biopsy was deemed inappropriate as a form of treatment after 2017,113 
the C dots are still believed to possess therapeutic effects by reduction in size of tumor and 
are currently under further investigation.203 Phase III trials of both concurrent triplet 
combination therapy (vemurafenib, cobimetinib, atezolizumab) and sequential combination 
therapy (vemurafenib and cobimetinib alone) in advanced melanoma patients are ongoing.204 
The results of the trials would allow better understanding of the safety and efficacy of 
targeted therapy and immunotherapy combinations.  
Most of the targeted theranostic probes for ovarian cancer are still in various phases of 
clinical trials, have yet to be approved by the FDA.205 For the triple-negative breast cancer, 
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only paclitaxel and irinotecan loaded liposomes, also known as EndoTAG-1 and MM-398 
have proceeded through clinical studies.206 Phase III trial of EndoTAG-1 in combination with 
gemcitabine is currently ongoing in patients with pancreatic cancer. Recently, Phase I study 
to understand the biodistribution of MM-398 and the feasibility of using ferumoxytol as a 
solid tumor and brain cancer imaging agent has been completed.  
Nanomaterials such as carbon nanotubes and graphene are not yet approved for clinical trials 
as wearable sensors, implantable devices, aid in clinical interventions and treatments of 
various diseases.108 Primary challenges including human health risks (biocompatibility, 
biological toxicity), environmental impact, selectivity for biomarkers detection, long-term 
stability, should be addressed before clinically approved graphene and its derivatives move 
forward.  
There are various clinical trials that have been terminated due to numerous reasons such as 
inadequate enrolment, variations in the clinical findings and no improvements compared to 
controls/placebos. For example, CALAA-01, a targeted nanocomplex that contains anti-
ribonucleotide reductase small interfering RNA (siRNA) has been terminated after Phase I. 
Despite showing the potential in solid tumor, the nature and complexity of CALAA-01 raised 
several concerns (possible immunostimulation, coagulopathic effects, kidney toxicity, off-
target deposition, hepatotoxicity), therefore hindering its clinical translation.207  
One of the flaws in clinical trials is the disconnection between mice and human models.202 
Nanomaterials showing positive theranostic results in in vitro and in vivo settings do not 
grant their applicability in clinical trials, mainly due to a combination of multiple complex 
bio-nano interactions in the body.68,208 Research on nanotheranostic nanomaterials is rapidly 
advancing to incorporate biocompatibility, specific targeting, advanced imaging and 
diagnosis, as well as localized drug delivery in the human body.12,17,23,56,138 An increase in 
knowledge of physiochemical properties of nanomaterials coupled with the design of 
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multifunctional theranostic platform and microenvironment-priming approaches is likely to 
radically expedite clinical approval of more nanotheranostic nanomaterials and bring them to 
clinical applications. 
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TABLE OF SUMMARY  













Solid tumors Ruthenium NPs 
(NKP-1339) 
Targeting of GRP78 




mean total clearance 
(CLtotal): 
164 mL/hour 
Targeting & therapy Phase I completed 
(2012) 
209 






tumor necrosis factor 
alpha (rhTNF) 
Size: 27 nm; liquid, 
intravenous injection; 















(hTf) targeting ligand 
& hydrophilic PEG 
(CALAA-01) 
Size: 70 nm; liquid, 
intravenous injection; 
siRNA is not 
chemically modified; 
1:1 charge ratio of 
positive charged 
polymer to negatively 
charge nucleic acid; 
endosomal disruption 
& siRNA release into 
Targeting & therapy 
(RNAi) 
Phase I terminated 
(2012), progressive 
disease was observed 
207,212 
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the cytoplasm of 




Colloidal gold NPs, 
bounded with 
recombinant human 
tumor necrosis factor 
alpha (rhTNF) & 
thiolyated PEG 
(CYT-6091) 
Size: 7-20 nm; intra-
tumour injection; 
well-tolerated doses 
at 50-600 μg/m2; 





Phase I completed 
(2009) 
210,213 
Breast cancer Liposome NPs 
encapsulating DOX 
& trastuzumab (for 
targeting of HER2 
receptor protein) 
(MM-302) 
Size: 100 nm; 
enhanced antitumor 
activity, activation of 
p53 protein levels 
phosphorylation/activ
ation; decreased 
Targeting & therapy  Phase II/III 
terminated (2017) 
(does not show 
benefit over control 
& confirmed via 
futility analysis) 
214 












Size: 1-10 nm; 
conjugation with 




cancer activity; in the 
form of topical cream 





Squamous cell cancer 




about 2 hours half-
life with minimal 
Targeting & therapy  Phase I completed 
(2015) 
216 










Size: 6-7 nm; 
superior brightness; 
enhanced tumor 
tissue retention with 
low background 
signal; portable & 
real-time optical 
detection of nodal 
metastases 





Head and neck 
cancer 
Ultrasuperparamagne
tic nanoparticle iron 
oxide (Ferumoxytol) 
Size: 17-31 nm; 3D 
quantitative tumor 
characterization 
Targeting & imaging 
(MRI) 
Phase I completed 
(2019) 
217 
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Atherosclerosis Gold NPs coated on 
silica/iron oxide 
shells 
Size: 90–150 nm; 
stenting & micro-
infusion of stem cells 
bearing NPs into the 
lesion 
Targeting & therapy 
(plasmonic 
photothermal & stem 
cell therapy) 




tic nanoparticle iron 
oxide (Ferumoxytol) 
Size: 17-31 nm; 4-6 
times enhanced 
phagocytosis; higher 




of heart muscle 
damage area  
Targeting & imaging N/A Completed 
(2012) 
219 
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40 to -60 mV) 








Size: 30 nm; 
monocrystalline; with 
long-circulating 




Targeting & imaging N/A completed 
(2009) 
221 
Brain metastases Gd NPs (AGuIX) Size: 4.5 nm; can be 
used in combination 
with fractionated 
stereotactic radiation 
Targeting & imaging 
(MRI) 
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in oligo brain 
metastases 
Gliosarcoma Spherical gold NPs 
carrying nucleic acids 
& drugs (NU-0129) 
Size: 13 nm; can 
cross the blood-brain 
barrier; targeting of 
Bcl2L12 gene to stop 
cancer cells from 
growing 






Lipid NPs Patisiran 
(ALN-TTR02) 
Size: 60-100 nm; 
liquid, intravenous 
injection; prevented 
the deterioration of 
left ventricular global 
longitudinal strain 
over 18 months 
Targeting & therapy 
(gene silencing) 
Phase III completed 
(2017) 
224 
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Thyroid cancer Lymphotrophic 
superparamagnetic 
NPs loaded with drug 
(Ferumoxytol) 
Size: 30 nm; 
intravenous injection 
(lyophilized iron 
oxide injected dose: 
2.6 mg per kg of 
body weight); 




lymph nodes (even 2 
nm)  





Prostate cancer Hafnium oxide NPs 
(NBTXR3) 




Targeting & therapy 
(radiotherapy)  









surface charge; stable 
in aqueous solution at 
pH 6-8; able to 
deposit high energy 
within tumors; 
chemically inert in 
cellular & subcellular 
systems; therapy 
activated by intensity 
modulated 
radiotherapy 
Silica NPs Size: sub-8 nm; 
intravenous  
injection; targeting of 
Targeting & imaging 
(PET/MRI) 
Phase I ongoing 
(estimated 
228 








uptake at prostate 
specific (PC-3) cells 
completion year 
2021) 
Magnetic iron oxide 










Size: 15.74 nm; 
surface charge: 
−58.06 ± 1.72 mV; 
preferential binding 
& accumulation in 
PC-3 cells; 2 times 
enhanced 
cytotoxicity; 10 times 
lesser dose required; 
possess double-
Targeting & imaging 
(MRI) 
Phase I completed 
(2015) 
104 
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receptor targeting and 
imaging capability  
Cervical cancer Ultrasuperparamagne
tic nanoparticle iron 
oxide (Ferumoxtran-
10) 
Size: 30 nm; 
intravenous  
injection; increased 
MRI sensitivity to 
detect lymph nodes 
metastasis  
Targeting & imaging N/A completed 
(2019) 
229 




Size: 4.5 nm; 
improved 
longitudinal 
relaxivity (4.87 s−1 
Theranostic agent 
(imaging, targeting & 
therapy)  
Phase I ongoing 
(2019) 
88 




mM−1 & r2/ r1 of 
1.46); a contrast of 
4.26 Hounsfield unit 
mM−1 (close to those 
of clinically used CT 
contrast agents) 




Size: 17-31 nm; 
intravenous injection; 
contrast agent for 
brain MRI; ultrahigh-
field MRI & phase 
contrast; highly 
sensitive 
Targeting & imaging 
(MRI) 




tic nanoparticle iron 
oxide (Ferumoxytol) 
Size: 17-31 nm; 
targeting of bombesin 
receptors; relaxivity: 
Targeting & imaging 
(MRI) 
Phase IV completed 
(2012) 
231 







Non-small cell lung 
cancer 





& hydrophilic PEG 
corona decorated 
with small molecule 
prostate-specific 
membrane antigen 







Targeting & therapy Phase II completed 
(2016) 
232 





refractory B cell 
malignancies 
Polyethylenimine 






initiation factor 5A 
(eIF5A) & plasmid-
based overexpression 
of a non-hypusinable 
eIF5A mutant 
(SNS01-T) 






progression in a 
number of B-cell 
malignancies 
Targeting & therapy 
(RNAi) 
Phase I/II recruitment 
status (2014) 
233 




Lipid NP, composed 
of cationic 
DOTIM/cholesterol 
liposomes & plasmid 
DNA (JVRS-100) 











Phase I completed 
(2017) 
234 
Parkinson's disease Gold nanocrystals, 
modified with 
montmorillonite 
Single crystallized in 
the face centred cubic 
lattice; with a 
preferential growth 
direction along the 
(111) plane; specific 
surface: 327–579 
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m2/g; large specific 
pore volumes ~0.7 
cm3/g; pore 
diameters: 0–10 nm; 
synthesized 
propargylamines with 
82–94 % yield & 





silver NPs (AgTive)  
Size: 50 nm; 10−9 
mol/l required for 
bactericidal activity; 
concentration of 
0.8 % in an active 
surface of 450 cm2/g 
polyurethane 
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CONCLUSION AND FUTURE PERSPECTIVE  
Nanotheranostics refers to the use of nanomaterials capable of providing concurrent 
diagnostics and therapeutics at the disease sites. In this review, we have discussed the key 
properties of different nanomaterials, and how these nanomaterials are designed and tuned to 
meet the selectivity and specificity of the target disease. The specific properties of the 
nanomaterials in terms of feasibility, drawbacks and their potential applications in 
nanotheranostics were presented.  
Both solid and liquid cancerous tumors are different in regard to their tumor vascularity and 
heterogeneity, which require different diagnostic treatment and targeting strategies. Au 
nanostructures are biocompatible and permit facile surface functionalization for wide 
biological applications. In addition, Au nanostructures serve as a good photothermal 
transducer. Conjugation of a photosensitizer on the Au-based nanoplatform could generate 
high singlet oxygen and activate PDT. Most of the nanomaterials presented here are stimuli-
responsive, able to kick-start the sequential theranostic effects and release the 
chemotherapeutic drugs only when reaching tumor sites. If the potential side effects of each 
drug are well-understood, future studies can be expected on the co-delivery of drug 
combinations in a single platform for broader pharmacological applications.  
Inorganic nanomaterials are relatively stable over large ranges of pH and temperature, yet, 
concerns are raised over their low biodegradation and biosafety issues. Modification of 
different molecules (targeting and imaging contrast agents, drugs) on the surface of the 
inorganic nanomaterials permits diverse applications of the nanomaterials. However, the 
characterization and fairly weak fundamental understanding of the structure-function 
correlations often restrict its predictive functions in nanotheranostics. Polymeric and lipid 
NPs are usually used as nano-vehicles for delivering therapeutics and diagnostics agents to 
the tumor sites, thanks to their biocompatibility and biostability features. Generally, the poor 
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spatial resolution, shallow tissue penetration and relatively low quantum yield are some of the 
challenges of NIR-emissive polymeric NPs in theranostics. Since each drug varies in their 
surface area and solubility, their loading mechanism into lipid NPs sometimes remain 
challenging. Knowledge of the drug loading mechanism allows optimal formulation of the 
nanocarrier system with theranostic properties and minimal limitations or potential side 
effects. 
Being one of the most interesting and versatile materials, graphene and its derivatives offer a 
relatively simple but highly integrated and multifunctional nanotheranostic platform for 
biomedical applications. Nevertheless, more systemic investigations are required to better 
understand its behavior, biodegradability and toxicological profiles in complex biological 
environment. 
Concerning nanotheranostic applications in liquid tumors, researches are still in its infancy 
compared to solid tumor. Most of the approaches done thus far are directed to the diagnosis 
and treatment of blood cancers, such as lymphoma and leukemia. It is surprising to note that 
although the physico-chemical scenario of blood cancers is different to solid tumors, the same 
types of nanomaterials are being used. This can be clearly observed in the use of metal NPs 
for thermal ablation in both solid and liquid tumors. In solid tumors, the nanomaterial is 
anchored to the surface of the tumor leading to an effective and non-invasive ablation, 
whereas in liquid tumor, the target element is in constant circulation and this can lead to 
ablation of adjacent tissue. The same phenomenon is observed with the use of polymeric and 
lipid NPs as drug delivery systems in both solid and liquid tumor, where it is not clear the 
different requirements in terms of blood-brain barrier penetration, stability and renal 
clearance. This question needs to be solved and more work should be carried out in order to 
push the nanotheranostics for in vivo applications in circulating tumors.  
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For neurodegenerative diseases, all the nanotheranostic strategies have been applied for the 
diagnosis and treatment of Alzheimer disease and interestingly the selection of the 
nanomaterial is based on the therapeutic strategy (inhibition of Aβ aggregation and Cu2+ ions 
chelation). In both cases, fluorescence imaging modality is selected as a cost-effective and 
simple alternative to MRI and PET. Moreover, both therapy strategies have proven to be 
effective in in vivo therapy of Alzheimer disease, although it would be important to develop 
them also for the other neurodegenerative diseases.  
The NPs used for the theranostics of autoimmune diseases can be colloidal-based or organic-
based. The nanomaterials are mostly designed for targeting of the scavenger receptor present 
on the activated macrophages. The NPs permit prolonged circulation in the bloodstream and 
subsequently controlled release of the therapeutic drugs at the inflammation sites. Safety 
concern (biodistribution in non-targeted tissues, potential inflammation, biodegradability, 
biocompatibility and clearance) is the biggest obstacle that hampers the clinical application of 
most of the nanomedicine of RA.  
For cardiovascular diseases, the research is mainly focused on the non-invasive imaging 
modalities such as MRI and NIR fluorescence for detection of atherosclerotic plaque. The 
pursuit of therapeutic agents for atherosclerosis and its potential impact remains an open field 
for research. Currently, there is less information about the dose, pharmacokinetics, long-term 
side effects and toxicology of the NPs employed in most of the studies. Future research 
should also be emphasized on more detailed biocompatibility (such as blood-half-life) and 
immunogenicity evaluation of the NPs, as well as development towards precision drug 
delivery and early detection of atherosclerotic plaque. 
Inorganic NPs as antibacterial agents still face drawbacks such as non-specific biological 
toxicity or potential long-term in vivo retention. Applications of metal-free antibacterial 
agents are limited by poor stability and biocompatibility, complicated synthetic steps, and 
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limited material structural tunability. Besides, the long-term biosafety of antibacterial 
nanomaterials is another big concern as it usually associated with possible risks including 
excessive or insufficient heating, undesired diffusion and potential impact on the immune 
system.  
Continuous and multiple pharmacological and physical approaches have been developed to 
overcome biological and physiological barriers of the nanomaterials in complex biological 
systems. The ideal size of the NPs is highly dependent on the cancer type, tumor site and the 
stage of the diseases. Overall, NPs with a tunable size between 10-100 nm is the most 
favorable in the development of cancer theranostics, mainly due to enhanced cellular uptake, 
biodistribution, blood circulation half-life, cellular uptake, tumor penetration and targeting at 
this size range.  
The pH value, antioxidant levels and enzymatic activity belong to endogenous stimuli; while 
light, ultrasound and magnetic are some of the examples of external stimuli. Theranostic 
applicability of external stimuli-responsive nanomaterials is less dependent on tumor type or 
pathological properties. Such nanomaterials can be applied at the diseases site in a controlled 
manner, but the efficacy is severally compromised in metastasized lesions. In contrast, 
theranostic efficacy of endogenous stimuli-sensitive nanomaterials is highly heterogeneous 
between different types of tumors/diseases. Moreover, staging (a process to determine if 
cancer has spread within the organ or to other parts of the body) is important to determine the 
stage of the cancer/disease. The design of nanomaterials (dose requirements, efficacy, side 
effects, etc.) must be tuned according to the pathological properties of tumors/diseases.  
Safety, efficiency and controllability are the major criteria in biomedical applications. Eco-
toxicological, biosafety and biocompatibility evaluation must be conducted for theranostic 
nanomaterials, taking into account factors including route of administration/exposure, 
biodistribution, biodegradability, long-term exposure, etc. The morphology, size distribution, 
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nature of interfaces (charges and surface chemistry) and colloidal stability of the 
nanomaterials in different media might influence the nanotoxicity of nanomaterials. The 
interaction of NPs with cell organelles also requires further studies as it plays a critical role in 
impacting the biogenesis and biological activities.  
No theranostic nanomaterials have been approved by the FDA for commercialization to date, 
mainly due to significant heterogeneity in the design, synthesis, safety and efficacy of the 
nanomaterials in clinical trials. The behavior of the nanomaterials in the dynamic 
physiological and pathological alterations in vivo is not well-defined too. Most of the current 
nanomaterials are in various phases of clinical trials, though the future perspective is brilliant. 
Future research should be focused on improving the clinical relevance and translational 
feasibility of nanomaterials for theranostic applications. The strength and limitations of each 
nanomaterial, particularly the potential side effects/toxicities, should be comprehensively 
understood upon developing them with robust efficacy and clinical benefit. Understanding of 
pharmacokinetic profile of nanomaterials in humans should be emphasized, along with 
clinical translation in appropriate animal models. After all the concerted efforts from 
multidisciplinary teams of chemist, pharmacists, physicists and engineers, it is believed that 
nanomaterials promise revolutionary potential as theranostic agents for a variety of clinical 
applications and improving the quality of life of the population.  
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VOCABULARY  
nanotheranostics, development of nanomedicine approaches for advanced theranostics 
(combined therapeutic and imaging/diagnostic features); nanomaterials, materials with one 
or more external dimensions in the nanoscale (sizes range from about 1-100 nm); 
photothermal therapy, thermal ablation of cancer cells with the use of photoabsorbing 
agents that could efficiently transfer the absorbed light energy into heat, subsequently leading 
to cell death; photodynamic therapy, an externally activatable treatment with the use of 
photosensitizer molecules to generate cytotoxic singlet or reactive oxygen species to kill 
cancer cells via oxidative stress; passive targeting, delivery of nanoparticles via enhanced 
permeability and retention effect in tumor or any leaky vasculature and anatomic barrier; 
active targeting, delivery of nanoparticles to the tissue of interest based on molecular, 
ligand/receptor or antibody-antigen recognition. More focused delivery with reduced 
potential side effects, toxicity and cost of drug/delivery; graphene, single-layered carbon 
atoms packed into a two-dimensional honeycomb lattice.  
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